<?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName archivearticle.dtd?>
<?SourceDTD.Version 2.3?>
<?ConverterInfo.XSLTName nlm2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Front Immunol</journal-id>
    <journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id>
    <journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
    <journal-title-group>
      <journal-title>Frontiers in Immunology</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1664-3224</issn>
    <publisher>
      <publisher-name>Frontiers Media S.A.</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10080220</article-id>
    <article-id pub-id-type="doi">10.3389/fimmu.2023.1103392</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Immunology</subject>
        <subj-group>
          <subject>Methods</subject>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>PathwayKO: An integrated platform for deciphering the systems-level signaling pathways</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Ai</surname>
          <given-names>Hannan</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="aff2" ref-type="aff">
          <sup>2</sup>
        </xref>
        <xref rid="aff3" ref-type="aff">
          <sup>3</sup>
        </xref>
        <xref rid="fn001" ref-type="author-notes">
          <sup>*</sup>
        </xref>
        <uri xlink:href="https://loop.frontiersin.org/people/1637412"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Meng</surname>
          <given-names>Fanmei</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <uri xlink:href="https://loop.frontiersin.org/people/1637218"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Ai</surname>
          <given-names>Yuncan</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="aff4" ref-type="aff">
          <sup>4</sup>
        </xref>
        <xref rid="fn001" ref-type="author-notes">
          <sup>*</sup>
        </xref>
        <uri xlink:href="https://loop.frontiersin.org/people/1561140"/>
      </contrib>
    </contrib-group>
    <aff id="aff1"><sup>1</sup><institution>State Key Laboratory for Biocontrol, School of Life Sciences, Sun Yat-sen University</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country></aff>
    <aff id="aff2"><sup>2</sup><institution>Department of Electrical and Computer Engineering, The Grainger College of Engineering, University of Illinois at Urbana-Champaign</institution>, <addr-line>Urbana, IL</addr-line>, <country>United States</country></aff>
    <aff id="aff3"><sup>3</sup><institution>National Center for Quality Supervision and Inspection of Automatic Equipment, National Center for Testing and Evaluation of Robots (Guangzhou), CRAT, SINOMACH-IT</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country></aff>
    <aff id="aff4"><sup>4</sup><institution>The Second Affiliated Hospital, Guangdong Provincial Key Laboratory of Allergy &amp; Clinical Immunology, Center for Inflammation, Immunity &amp; Immune-mediated Disease, Sino-French Hoffmann Institute, Guangzhou Medical University</institution>, <addr-line>Guangzhou, Guangdong</addr-line>, <country>China</country></aff>
    <author-notes>
      <fn fn-type="edited-by">
        <p>Edited by: Zewen Kelvin Tuong, The University of Queensland, Australia</p>
      </fn>
      <fn fn-type="edited-by">
        <p>Reviewed by: Mauricio Alberto Quimbaya, Pontificia Universidad Javeriana Cali, Colombia; Jan Patrick Pett, Wellcome Sanger Institute (WT), United Kingdom</p>
      </fn>
      <corresp id="fn001">*Correspondence: Hannan Ai, <email xlink:href="mailto:Allenai94@icloud.com">Allenai94@icloud.com</email>; Yuncan Ai, <email xlink:href="mailto:Lssayc@mail.sysu.edu">Lssayc@mail.sysu.edu.cn</email>
</corresp>
      <fn fn-type="other" id="fn002">
        <p>This article was submitted to Systems Immunology, a section of the journal Frontiers in Immunology</p>
      </fn>
    </author-notes>
    <pub-date pub-type="epub">
      <day>23</day>
      <month>3</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2023</year>
    </pub-date>
    <volume>14</volume>
    <elocation-id>1103392</elocation-id>
    <history>
      <date date-type="received">
        <day>20</day>
        <month>11</month>
        <year>2022</year>
      </date>
      <date date-type="accepted">
        <day>01</day>
        <month>3</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>Copyright © 2023 Ai, Meng and Ai</copyright-statement>
      <copyright-year>2023</copyright-year>
      <copyright-holder>Ai, Meng and Ai</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
      </license>
    </permissions>
    <abstract>
      <p>Systems characterization of immune landscapes in health, disease and clinical intervention cases is a priority in modern medicine. High-throughput transcriptomes accumulated from gene-knockout (KO) experiments are crucial for deciphering target KO signaling pathways that are impaired by KO genes at the systems-level. There is a demand for integrative platforms. This article describes the PathwayKO platform, which has integrated state-of-the-art methods of pathway enrichment analysis, statistics analysis, and visualizing analysis to conduct cutting-edge integrative pathway analysis in a pipeline fashion and decipher target KO signaling pathways at the systems-level. We focus on describing the methodology, principles and application features of PathwayKO. First, we demonstrate that the PathwayKO platform can be utilized to comprehensively analyze real-world mouse KO transcriptomes (GSE22873 and GSE24327), which reveal systemic mechanisms underlying the innate immune responses triggered by non-infectious extensive hepatectomy (2 hours after 85% liver resection surgery) and infectious CASP-model sepsis (12 hours after CASP-model surgery). Strikingly, our results indicate that both cases hit the same core set of 21 KO MyD88-associated signaling pathways, including the Toll-like receptor signaling pathway, the NFκB signaling pathway, the MAPK signaling pathway, and the PD-L1 expression and PD-1 checkpoint pathway in cancer, alongside the pathways of bacterial, viral and parasitic infections. These findings suggest common fundamental mechanisms between these immune responses and offer informative cues that warrant future experimental validation. Such mechanisms in mice may serve as models for humans and ultimately guide formulating the research paradigms and composite strategies to reduce the high mortality rates of patients in intensive care units who have undergone successful traumatic surgical treatments. Second, we demonstrate that the PathwayKO platform model-based assessments can effectively evaluate the performance difference of pathway analysis methods when benchmarked with a collection of proper transcriptomes. Together, such advances in methods for deciphering biological insights at the systems-level may benefit the fields of bioinformatics, systems immunology and beyond.</p>
    </abstract>
    <kwd-group>
      <kwd>systems immunology</kwd>
      <kwd>signaling pathways</kwd>
      <kwd>network analysis</kwd>
      <kwd>inflammation</kwd>
      <kwd>innate immunity</kwd>
      <kwd>microbial immunity</kwd>
      <kwd>bioinformatics</kwd>
    </kwd-group>
    <funding-group>
      <funding-statement>This work was supported by a grant-in-aid from the National Science and Technology Major Programs of China (2014ZX0801105B-002) and the Supercomputing Program of National Natural Science Foundation of China (No. U1501501-534) to YA.</funding-statement>
    </funding-group>
    <counts>
      <fig-count count="13"/>
      <table-count count="2"/>
      <equation-count count="1"/>
      <ref-count count="47"/>
      <page-count count="25"/>
      <word-count count="12023"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="s1">
    <label>1</label>
    <title>Introduction</title>
    <p>Systems characterization of immune landscapes in health, disease, and clinical intervention cases has become a priority in modern medicine. For instance, to reduce the high mortality rates of patients in the intensive care unit (ICU), insights into the complex mechanisms underlying systems immunology triggered by infectious or non-infectious traumatic surgical treatments must be further investigated through both bench-experimental and computational analyses (<xref rid="B1" ref-type="bibr">1</xref>–<xref rid="B4" ref-type="bibr">4</xref>). High-throughput transcriptomes accumulated in gene-knockout (KO) experiments are crucial for deciphering target KO signaling pathways that are impaired by KO genes at the systems-level (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B5" ref-type="bibr">5</xref>). KEGG pathways, as dominant examples, are curated manually with literature and experimental evidence, thus intuitively visualizing the signaling pathways that are supported by the literature and/or experimental evidence (<xref rid="B6" ref-type="bibr">6</xref>). However, existing methods of pathway enrichment analysis may not produce consistent results, or identify true target signaling pathways owing to intrinsic defects, as discussed in the literature (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>).</p>
    <p>Pathway enrichment analysis methods have evolved over decades from non-topology-based to topology-based approaches; the latter category generally performs better than the former category (<xref rid="B5" ref-type="bibr">5</xref>). The eminent non-topology-based methods include SAFE (<xref rid="B9" ref-type="bibr">9</xref>), GSEA (<xref rid="B10" ref-type="bibr">10</xref>), GSA (<xref rid="B11" ref-type="bibr">11</xref>) and PADOG (<xref rid="B12" ref-type="bibr">12</xref>). These methods employ entire gene sets. Unlike over-representation methods (e.g., the hypergeometric test) where a hypergeometric or binomial distribution is normally assumed (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>), advanced methods (e.g., SAFE and GSEA) are built on empirical distribution functions (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>). These statistical methods may not fit real data, thus preventing accurate predictions, as discussed in the literature (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B14" ref-type="bibr">14</xref>). The pioneering topology-based methods include ROntoTools_PE (<xref rid="B15" ref-type="bibr">15</xref>), SPIA (<xref rid="B16" ref-type="bibr">16</xref>) and ROntoTools_pDIS (<xref rid="B5" ref-type="bibr">5</xref>). These methods deploy differentially expressed genes (DEGs) with topology information on gene-gene interactions (<xref rid="B5" ref-type="bibr">5</xref>). Nonetheless, the criteria for selecting DEGs remain debatable (<xref rid="B5" ref-type="bibr">5</xref>). For instance, by a traditional approach, an arbitrary number of genes (e.g., top 5% or 10% of total genes present in the available KEGG pathways) are selected by using an arbitrary cutoff <italic>p</italic>-value (e.g., <italic>p</italic>&lt;0.05) or fold-change (e.g., absolute log2FC&gt;1.5) or their conjunction (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>). These arbitrary cutoffs to select DEGs hinder a fair and reasonable comparisons under the same context, as discussed in the literature (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B7" ref-type="bibr">7</xref>). Meanwhile, approaches to evaluating performance differences among pathway analysis methods have recently evolved from traditional disease-target-pathways (<xref rid="B7" ref-type="bibr">7</xref>) toward known-KO pathways (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B17" ref-type="bibr">17</xref>). High-throughput transcriptomes accumulated in gene-KO experiments have offered unique opportunities to decipher target KO signaling pathways that are truly impaired by KO genes at the systems-level (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B5" ref-type="bibr">5</xref>). Thus, developing integrative platforms to conduct cutting-edge integrative pathway analysis and to evaluate the performance difference of methods has become an imminent frontier of research in the field.</p>
    <p>We recently developed an in-house PathwayKO package and used it to analyze a transcriptome (GSE24327) that was recovered from mouse spleens 12 hours after a colon ascendens stent peritonitis (CASP)-model surgery coupled with <italic>Myd88</italic> gene-KO experiments (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). The original bench-experiments suggested that the MyD88-deficient phenotype attenuated proinflammatory responses and thus reduced the mortality rate after CASP-model surgery (<xref rid="B2" ref-type="bibr">2</xref>). To elucidate the mechanisms underlying the observed phenomena, we designed the following three subtypes of GSE24327 data according to the original bench-experiments (<xref rid="B2" ref-type="bibr">2</xref>): GSE24327_A (septic KO MyD88 vs. septic WT) for comparing septic null (<italic>Myd88</italic>
<sup>–/–</sup>) with septic wild-type mice, GSE24327_B (septic KO MyD88 vs. untreated WT) for comparing septic null (<italic>Myd88</italic>
<sup>–/–</sup>) with untreated wild-type mice, and GSE24327_C (septic WT vs. untreated WT) for comparing septic wild-type with untreated wild-type mice (<xref rid="B1" ref-type="bibr">1</xref>). With the PathwayKO package, we successfully identified 21 KO MyD88-associated signaling pathways from each subtype and illustrated numerous key regulators (including ligands, receptors, adapters, transducers, transcription factors and cytokines) that were coordinately, significantly and differentially expressed at the systems-level, and were precisely marked on those target KO signaling pathways (<xref rid="B1" ref-type="bibr">1</xref>). Our results revealed the mechanisms underlying systems immunology triggered by the infectious CASP-model sepsis from the bioinformatics analysis perspective (<xref rid="B1" ref-type="bibr">1</xref>). We discussed the observed phenomena, including the “systemic syndrome”, “cytokine storm”, and “KO MyD88 attenuation”, as well as the proposed hypothesis of “spleen-mediated immune-cell infiltration” (<xref rid="B1" ref-type="bibr">1</xref>). We thereby anticipated that these mechanisms may serve as models for humans, and ultimately facilitate formulating research paradigms and composite strategies for the early diagnosis and prevention of sepsis (<xref rid="B1" ref-type="bibr">1</xref>). This case study appeals that the PathwayKO package has the potential to be constantly updated and widely used by the community.</p>
    <p>The present article aims to describe the PathwayKO platform, focusing on its methodology, principles and application features. We applied the platform to analyze a real-world transcriptome (GSE22873) as a case study to elucidate the mechanisms underlying systems immunology triggered by non-infectious extensive hepatectomy in single- and double-null mice (<xref rid="B3" ref-type="bibr">3</xref>). We illustrate that the platform incorporates state-of-the-art methods of pathway enrichment analysis, statistics analysis, and visualizing analysis to conduct the cutting-edge integrative pathway enrichment analysis, which allows excavating target KO signaling pathways at the systems-level. We highlight that this integrated platform possesses but is not limited to the following advantageous features:</p>
    <list list-type="bullet">
      <list-item>
        <p>The differentially expressed genes (DEGs) are statistically determined from data and are ready for pathway analysis under the same context;</p>
      </list-item>
      <list-item>
        <p>The ROC curves and key metrics are simultaneously calculated, both across methods and across data, in a pipeline fashion;</p>
      </list-item>
      <list-item>
        <p>The target KO signaling pathways are significantly identified and differentially marked by key regulators, which are coordinately, significantly and differentially expressed at the systems-level;</p>
      </list-item>
      <list-item>
        <p>The ROC curve-based statistics analysis is conducted under the same conditions to evaluate the performance difference of methods;</p>
      </list-item>
      <list-item>
        <p>Both interactive and pipeline modes can be chosen for desired computations.</p>
      </list-item>
    </list>
    <p>Moreover, we demonstrate the application of the PathwayKO platform model-based assessments, and the results suggest that the PathwayKO platform can effectively evaluate the performance difference of pathway analysis methods when benchmarked on a collection of proper transcriptomes.</p>
  </sec>
  <sec id="s2">
    <label>2</label>
    <title>Framework overview of the PathwayKO platform</title>
    <p>The PathwayKO platform (<xref rid="f1" ref-type="fig"><bold>Figure 1</bold></xref>) currently incorporates and drives a set of internal and external packages (<xref rid="f1" ref-type="fig"><bold>Figure 1A</bold></xref>) coupled with diverse dependencies (<xref rid="f1" ref-type="fig"><bold>Figure 1B</bold></xref>) to pursue the integrative (I) preprocessing, (II) ROC-AUC calculating, (III) statistics analyzing, and (IV) visualizing processes. All external packages are adapted from the literature (<xref rid="B9" ref-type="bibr">9</xref>–<xref rid="B20" ref-type="bibr">20</xref>). The PathwayKO platform as systems software has integrated state-of-the-art methods of pathway enrichment analysis, statistics analysis, and visualizing analysis (<xref rid="f1" ref-type="fig"><bold>Figures 1A, B</bold></xref>), which work in a pipeline fashion (<xref rid="f1" ref-type="fig"><bold>Figures 1C, D</bold></xref>). The pathway enrichment analysis methods (<xref rid="f1" ref-type="fig"><bold>Figure 1A</bold></xref>) include the packages of non-topology- and topology-based methods, such as SAFE (<xref rid="B9" ref-type="bibr">9</xref>), GSEA (<xref rid="B10" ref-type="bibr">10</xref>), GSA (<xref rid="B11" ref-type="bibr">11</xref>), PADOG (<xref rid="B12" ref-type="bibr">12</xref>), ROntoTools_PE (<xref rid="B15" ref-type="bibr">15</xref>), ROntoTools_pDIS (<xref rid="B5" ref-type="bibr">5</xref>) and SPIA (<xref rid="B16" ref-type="bibr">16</xref>), which are widely used by the community. The statistics analysis methods (<xref rid="f1" ref-type="fig"><bold>Figure 1B</bold></xref>) include the packages of changepoint (<xref rid="B18" ref-type="bibr">18</xref>) and pROC (<xref rid="B19" ref-type="bibr">19</xref>). The visualizing analysis methods (<xref rid="f1" ref-type="fig"><bold>Figure 1B</bold></xref>) include the packages of pROC (<xref rid="B19" ref-type="bibr">19</xref>) and Pathview (<xref rid="B20" ref-type="bibr">20</xref>).</p>
    <fig position="float" id="f1">
      <label>Figure 1</label>
      <caption>
        <p>Framework overview of the PathwayKO platform. <bold>(A)</bold> Framework of the PathwayKO platform as systems software. <bold>(B)</bold> Processes, modules, methods and dependencies integrated in the PathwayKO platform. <bold>(C)</bold> Pipeline analysis with a collection of data, both across methods and across data. <bold>(D)</bold> Parallel computation.</p>
      </caption>
      <graphic xlink:href="fimmu-14-1103392-g001" position="float"/>
    </fig>
  </sec>
  <sec id="s3">
    <label>3</label>
    <title>Methodology, principles and application features of the PathwayKO platform</title>
    <p>This article aims to describe the PathwayKO platform from the perspectives of methodology, principles and application features with results from some of its modules (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Figures S1</bold></xref>-<xref rid="SM1" ref-type="supplementary-material"><bold>S4</bold></xref>), as exemplified by real-world case studies of GSE24327 (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>) and GSE22873 (<xref rid="B3" ref-type="bibr">3</xref>); these data were downloaded (as of March 19, 2021) from <ext-link xlink:href="https://ncbi.nlm.nih.gov/geo/" ext-link-type="uri">https://ncbi.nlm.nih.gov/geo/</ext-link>. The 333 mouse KEGG signaling pathways were downloaded (as of March 19, 2021) from <ext-link xlink:href="https://www.kegg.jp/" ext-link-type="uri">https://www.kegg.jp/</ext-link>. Users should install the PathwayKO platform and utilize this platform to complete tasks following the tutorials step-by-step, provided as online supplemental materials (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Figures S1</bold></xref>-<xref rid="SM1" ref-type="supplementary-material"><bold>S4</bold></xref>). Users may also follow instructions in the user’s manual offered at <ext-link xlink:href="https://github.com/allenaigit/pathwayko/tree/main/inst/docs/Users_manual.pdf" ext-link-type="uri">https://github.com/allenaigit/pathwayko/tree/main/inst/docs/Users_manual.pdf</ext-link>.</p>
    <sec id="s3_1">
      <label>3.1</label>
      <title>Preprocessing process</title>
      <sec id="s3_1_1">
        <label>3.1.1</label>
        <title>Feature 1: Automatic generation of intermediate data from one data</title>
        <p>The preprocess module can preprocess the given GEO data (GSEXXX_RAW.tar and GSEXXX_series_matrix.txt.gz) stored in the assigned working directory (e.g., PathwayKO_platform) by utilizing the oligo (<xref rid="B21" ref-type="bibr">21</xref>) and limma (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>) packages for RMA normalization, which will generate intermediate data (pData.csv and PREP.RData). The preprocess module can handle most types of GEO data produced by the major types of machines thus far. Meanwhile, the makeSPIAdata module adapted from the SPIA package (<xref rid="B16" ref-type="bibr">16</xref>) can parse KEGG pathways to generate intermediate data (mmuSPIA.RData) ready for pathway enrichment analysis by topology-based methods (SPIA, ROntoTools_PE, and ROntoTools_pDIS). Only topology-based methods can utilize the topology information of gene-gene interactions (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B16" ref-type="bibr">16</xref>). All resulting output files are stored in the new directories automatically created and named after the given data (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Figure S2</bold></xref>).</p>
      </sec>
    </sec>
    <sec id="s3_2">
      <label>3.2</label>
      <title>ROC-AUC calculating process</title>
      <sec id="s3_2_1">
        <label>3.2.1</label>
        <title>Feature 2: Automatic selection of DEGs from one data</title>
        <p>The main module pathwayko can automatically select DEGs through enabling the HES (high-edge-score) approach (<xref rid="B17" ref-type="bibr">17</xref>), in addition to classical approaches (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>). The main module pathwayko drives the external changepoint package (<xref rid="B18" ref-type="bibr">18</xref>), by which the change-point analysis method (see <xref rid="f1" ref-type="fig"><bold>Figure 1</bold></xref>) makes a statistical decision on choosing the differentially expressed genes (DEGs) based on the distribution of edge scores (<xref rid="f2" ref-type="fig"><bold>Figure 2</bold></xref>) that are constructed from data (<xref rid="B17" ref-type="bibr">17</xref>). The resulting output directory will be automatically created and named after the given data; the directory contains a set of output files including the list of DEGs, the list of knockout (KO) KEGG pathways, and the KO gene-associated subnetwork.</p>
        <fig position="float" id="f2">
          <label>Figure 2</label>
          <caption>
            <p>Schema of the high-edge-score (HES) approach with the change-point analysis method for statistically selecting differentially expressed genes. Explanations are presented in the main text. <bold>(A)</bold> A global graph is constructed. <bold>(B)</bold> An edge score for two genes (X, Y) in the global graph is calculated. <bold>(C)</bold> A change-point is statistically determined. <bold>(D)</bold> High score edges are statistically determined. <bold>(E)</bold> The distribution of edge scores is generated with each of three optional HES thresholds (HES1, HES2 and HES3).</p>
          </caption>
          <graphic xlink:href="fimmu-14-1103392-g002" position="float"/>
        </fig>
        <p>The principles behind the high-edge-score (HES) approach and the change-point analysis method for statistically selecting differentially expressed genes (DEGs) were modified from the literature (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>), as briefly depicted below (<xref rid="f2" ref-type="fig"><bold>Figure 2</bold></xref>). First, a global graph is constructed (<xref rid="f2" ref-type="fig"><bold>Figure 2A</bold></xref>) by the external KEGGgraph package (<xref rid="B24" ref-type="bibr">24</xref>) based on available KEGG pathways (<xref rid="B6" ref-type="bibr">6</xref>); this graph comprises all known interactions among the entire gene sets present in the KEGG pathways. Second, the edge scores for all edges in the global graph are calculated (<xref rid="f2" ref-type="fig"><bold>Figure 2B</bold></xref>). Given two genes (X and Y) connected by an edge in the global graph, suppose <italic>FC<sub>X</sub>
</italic> and <italic>FC<sub>Y</sub>
</italic> are the values of the expression fold-change (FC) of X and Y, respectively, while <italic>pX</italic> and <italic>pY</italic> are the probability of observing <italic>FC<sub>X</sub>
</italic> and <italic>FC<sub>Y</sub>
</italic> just by chance, then the edge score between X and Y is calculated by the following formula (1):</p>
        <disp-formula>
          <label>(1)</label>
          <mml:math id="M1" display="block" overflow="scroll">
            <mml:mrow>
              <mml:mi>E</mml:mi>
              <mml:mi>d</mml:mi>
              <mml:mi>g</mml:mi>
              <mml:mi>e</mml:mi>
              <mml:mi>S</mml:mi>
              <mml:mi>c</mml:mi>
              <mml:mi>o</mml:mi>
              <mml:mi>r</mml:mi>
              <mml:msub>
                <mml:mi>e</mml:mi>
                <mml:mrow>
                  <mml:mi>X</mml:mi>
                  <mml:mi>Y</mml:mi>
                </mml:mrow>
              </mml:msub>
              <mml:mo>=</mml:mo>
              <mml:mrow>
                <mml:mo>|</mml:mo>
                <mml:mrow>
                  <mml:mi>F</mml:mi>
                  <mml:msub>
                    <mml:mi>C</mml:mi>
                    <mml:mi>X</mml:mi>
                  </mml:msub>
                </mml:mrow>
                <mml:mo>|</mml:mo>
              </mml:mrow>
              <mml:mo>·</mml:mo>
              <mml:mo stretchy="false">(</mml:mo>
              <mml:mn>1</mml:mn>
              <mml:mo>−</mml:mo>
              <mml:mi>p</mml:mi>
              <mml:mi>X</mml:mi>
              <mml:mo stretchy="false">)</mml:mo>
              <mml:mo>+</mml:mo>
              <mml:mrow>
                <mml:mo>|</mml:mo>
                <mml:mrow>
                  <mml:mi>F</mml:mi>
                  <mml:msub>
                    <mml:mi>C</mml:mi>
                    <mml:mi>Y</mml:mi>
                  </mml:msub>
                </mml:mrow>
                <mml:mo>|</mml:mo>
              </mml:mrow>
              <mml:mo>·</mml:mo>
              <mml:mo stretchy="false">(</mml:mo>
              <mml:mn>1</mml:mn>
              <mml:mo>−</mml:mo>
              <mml:mi>p</mml:mi>
              <mml:mi>Y</mml:mi>
              <mml:mo stretchy="false">)</mml:mo>
            </mml:mrow>
          </mml:math>
        </disp-formula>
        <p>where the FC value for gene X (or Y), <italic>FC<sub>X</sub>
</italic> (or <italic>FC<sub>Y</sub>
</italic>), is calculated by comparing the expression values of KO samples versus normal samples in each data. The <italic>p</italic>-value for gene X (or Y), <italic>pX</italic> (or <italic>pY</italic>), is calculated between the same groups (i.e., KO samples <italic>vs</italic>. normal samples) by using a moderated <italic>t</italic>-test (<xref rid="B17" ref-type="bibr">17</xref>). The FC values and <italic>p</italic>-values for all of these genes are calculated by using the functions eBayes and topTable from the external limma package (<xref rid="B23" ref-type="bibr">23</xref>). Third, a change-point is statistically determined (<xref rid="f2" ref-type="fig"><bold>Figure 2C</bold></xref>) by using the change-point analysis method from the external changepoint package (<xref rid="B18" ref-type="bibr">18</xref>), where a change-point is defined to be an inflection point after which the distribution curve becomes flat (<xref rid="B18" ref-type="bibr">18</xref>). Fourth, important edges are statistically determined (<xref rid="f2" ref-type="fig"><bold>Figure 2D</bold></xref>). They are connected by DEGs that are determined by a chosen HES threshold once initialized. Such DEGs connecting important edges are statistically selected, and ready for subsequent pathway enrichment analysis. Fifth, the distribution of edge scores is generated with three optional HES thresholds defined (<xref rid="f2" ref-type="fig"><bold>Figure 2E</bold></xref>). HES1 is the least HES (the lower boundary of the change point), the beginning of the flat area of a curve, recommended as default; HES2 is the extra 25% HES (25% safety margin of the change point), top 75% of the remaining scores to avoid selecting an overwhelming number of DEGs that may introduce false positives; and HES3 is the maximal HES (the upper boundary of the change point), the last edge connected by last two genes with the highest score. Finally, the differentially expressed genes (DEGs) are statistically selected by HES1, HES2 or HES3.</p>
      </sec>
      <sec id="s3_2_2">
        <label>3.2.2</label>
        <title>Feature 3: Building ROC curves and calculating key metrics in a pipeline fashion from one data</title>
        <p>The main module pathwayko can conduct the desired computations in a pipeline fashion, i.e., across methods over one data (see <xref rid="f1" ref-type="fig"><bold>Figure 1</bold></xref>). These computations include (i) building an ROC curve, (ii) computing the key metrics (<xref rid="T1" ref-type="table"><bold>Table 1</bold></xref>), (iii) computing the AUC (with 95% CI, confidence interval) for the full area under the entire ROC curve, (iv) computing the partial AUCs (pAUC_SP and pAUC_SE) for the specific regions focusing on 90–100% specificity and sensitivity in both original and corrected formats (<xref rid="B25" ref-type="bibr">25</xref>), and (v) computing the 95% CIs for specificity and sensitivity. The entire set of key metrics (<xref rid="T1" ref-type="table"><bold>Table 1</bold></xref>) for one data are then formatted as a summary output file (SUM.RData). The resulting output files are stored in a new directory automatically generated and named after the data. Such batch-computations intensively consume computing resources (CPUs, memory and storage). This is a time-limiting step.</p>
        <table-wrap position="float" id="T1">
          <label>Table 1</label>
          <caption>
            <p>Key metrics used for the ROC curve-based statistics analysis.</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th valign="middle" align="left" rowspan="1" colspan="1">Metrics</th>
                <th valign="middle" align="center" rowspan="1" colspan="1">Definition</th>
                <th valign="middle" align="center" rowspan="1" colspan="1"/>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td valign="middle" align="left" rowspan="1" colspan="1">False discovery rate (FDR)</td>
                <td valign="middle" align="center" rowspan="1" colspan="1">
                  <inline-formula>
                    <mml:math id="im1" display="inline" overflow="scroll">
                      <mml:mrow>
                        <mml:mi>F</mml:mi>
                        <mml:mi>D</mml:mi>
                        <mml:mi>R</mml:mi>
                        <mml:mo>=</mml:mo>
                        <mml:mfrac>
                          <mml:mrow>
                            <mml:mi>F</mml:mi>
                            <mml:mi>P</mml:mi>
                            <mml:mi>K</mml:mi>
                            <mml:mi>O</mml:mi>
                          </mml:mrow>
                          <mml:mrow>
                            <mml:mi>F</mml:mi>
                            <mml:mi>P</mml:mi>
                            <mml:mi>K</mml:mi>
                            <mml:mi>O</mml:mi>
                            <mml:mo>+</mml:mo>
                            <mml:mi>T</mml:mi>
                            <mml:mi>P</mml:mi>
                            <mml:mi>K</mml:mi>
                            <mml:mi>O</mml:mi>
                          </mml:mrow>
                        </mml:mfrac>
                      </mml:mrow>
                    </mml:math>
                  </inline-formula>
                </td>
                <td valign="middle" align="left" rowspan="1" colspan="1">(<xref rid="B2" ref-type="bibr">2</xref>)</td>
              </tr>
              <tr>
                <td valign="middle" align="left" rowspan="1" colspan="1">False positive rate (FPR)</td>
                <td valign="middle" align="center" rowspan="1" colspan="1">
                  <inline-formula>
                    <mml:math id="im2" display="inline" overflow="scroll">
                      <mml:mrow>
                        <mml:mi>F</mml:mi>
                        <mml:mi>P</mml:mi>
                        <mml:mi>R</mml:mi>
                        <mml:mo>=</mml:mo>
                        <mml:mfrac>
                          <mml:mrow>
                            <mml:mi>F</mml:mi>
                            <mml:mi>P</mml:mi>
                            <mml:mi>K</mml:mi>
                            <mml:mi>O</mml:mi>
                          </mml:mrow>
                          <mml:mrow>
                            <mml:mi>F</mml:mi>
                            <mml:mi>P</mml:mi>
                            <mml:mi>K</mml:mi>
                            <mml:mi>O</mml:mi>
                            <mml:mo>+</mml:mo>
                            <mml:mi>T</mml:mi>
                            <mml:mi>N</mml:mi>
                            <mml:mi>K</mml:mi>
                            <mml:mi>O</mml:mi>
                          </mml:mrow>
                        </mml:mfrac>
                      </mml:mrow>
                    </mml:math>
                  </inline-formula>
                </td>
                <td valign="middle" align="left" rowspan="1" colspan="1">(<xref rid="B3" ref-type="bibr">3</xref>)</td>
              </tr>
              <tr>
                <td valign="middle" align="left" rowspan="1" colspan="1">False negative rate (FNR)</td>
                <td valign="middle" align="center" rowspan="1" colspan="1">
                  <inline-formula>
                    <mml:math id="im3" display="inline" overflow="scroll">
                      <mml:mrow>
                        <mml:mi>F</mml:mi>
                        <mml:mi>N</mml:mi>
                        <mml:mi>R</mml:mi>
                        <mml:mo>=</mml:mo>
                        <mml:mfrac>
                          <mml:mrow>
                            <mml:mi>F</mml:mi>
                            <mml:mi>N</mml:mi>
                            <mml:mi>K</mml:mi>
                            <mml:mi>O</mml:mi>
                          </mml:mrow>
                          <mml:mrow>
                            <mml:mi>F</mml:mi>
                            <mml:mi>N</mml:mi>
                            <mml:mi>K</mml:mi>
                            <mml:mi>O</mml:mi>
                            <mml:mo>+</mml:mo>
                            <mml:mi>T</mml:mi>
                            <mml:mi>P</mml:mi>
                            <mml:mi>K</mml:mi>
                            <mml:mi>O</mml:mi>
                          </mml:mrow>
                        </mml:mfrac>
                      </mml:mrow>
                    </mml:math>
                  </inline-formula>
                </td>
                <td valign="middle" align="left" rowspan="1" colspan="1">(<xref rid="B4" ref-type="bibr">4</xref>)</td>
              </tr>
              <tr>
                <td valign="middle" align="left" rowspan="1" colspan="1">True positive rate (TPR)</td>
                <td valign="middle" align="center" rowspan="1" colspan="1">
                  <inline-formula>
                    <mml:math id="im4" display="inline" overflow="scroll">
                      <mml:mrow>
                        <mml:mi>T</mml:mi>
                        <mml:mi>P</mml:mi>
                        <mml:mi>R</mml:mi>
                        <mml:mrow>
                          <mml:mo stretchy="false">(</mml:mo>
                          <mml:mrow>
                            <mml:mi>S</mml:mi>
                            <mml:mi>e</mml:mi>
                            <mml:mi>n</mml:mi>
                            <mml:mi>s</mml:mi>
                            <mml:mi>i</mml:mi>
                            <mml:mi>t</mml:mi>
                            <mml:mi>i</mml:mi>
                            <mml:mi>v</mml:mi>
                            <mml:mi>i</mml:mi>
                            <mml:mi>t</mml:mi>
                            <mml:mi>y</mml:mi>
                          </mml:mrow>
                          <mml:mo stretchy="false">)</mml:mo>
                        </mml:mrow>
                        <mml:mo>=</mml:mo>
                        <mml:mfrac>
                          <mml:mrow>
                            <mml:mi>T</mml:mi>
                            <mml:mi>P</mml:mi>
                            <mml:mi>K</mml:mi>
                            <mml:mi>O</mml:mi>
                          </mml:mrow>
                          <mml:mrow>
                            <mml:mi>T</mml:mi>
                            <mml:mi>P</mml:mi>
                            <mml:mi>K</mml:mi>
                            <mml:mi>O</mml:mi>
                            <mml:mo>+</mml:mo>
                            <mml:mi>F</mml:mi>
                            <mml:mi>N</mml:mi>
                            <mml:mi>K</mml:mi>
                            <mml:mi>O</mml:mi>
                          </mml:mrow>
                        </mml:mfrac>
                      </mml:mrow>
                    </mml:math>
                  </inline-formula>
                </td>
                <td valign="middle" align="left" rowspan="1" colspan="1">(<xref rid="B5" ref-type="bibr">5</xref>)</td>
              </tr>
              <tr>
                <td valign="middle" align="left" rowspan="1" colspan="1">True negative rate (TNR)</td>
                <td valign="middle" align="center" rowspan="1" colspan="1">
                  <inline-formula>
                    <mml:math id="im5" display="inline" overflow="scroll">
                      <mml:mrow>
                        <mml:mi>T</mml:mi>
                        <mml:mi>N</mml:mi>
                        <mml:mi>R</mml:mi>
                        <mml:mrow>
                          <mml:mo stretchy="false">(</mml:mo>
                          <mml:mrow>
                            <mml:mi>S</mml:mi>
                            <mml:mi>p</mml:mi>
                            <mml:mi>e</mml:mi>
                            <mml:mi>c</mml:mi>
                            <mml:mi>i</mml:mi>
                            <mml:mi>f</mml:mi>
                            <mml:mi>i</mml:mi>
                            <mml:mi>c</mml:mi>
                            <mml:mi>i</mml:mi>
                            <mml:mi>t</mml:mi>
                            <mml:mi>y</mml:mi>
                          </mml:mrow>
                          <mml:mo stretchy="false">)</mml:mo>
                        </mml:mrow>
                        <mml:mo>=</mml:mo>
                        <mml:mfrac>
                          <mml:mrow>
                            <mml:mi>T</mml:mi>
                            <mml:mi>N</mml:mi>
                            <mml:mi>K</mml:mi>
                            <mml:mi>O</mml:mi>
                          </mml:mrow>
                          <mml:mrow>
                            <mml:mi>T</mml:mi>
                            <mml:mi>N</mml:mi>
                            <mml:mi>K</mml:mi>
                            <mml:mi>O</mml:mi>
                            <mml:mo>+</mml:mo>
                            <mml:mi>F</mml:mi>
                            <mml:mi>P</mml:mi>
                            <mml:mi>K</mml:mi>
                            <mml:mi>O</mml:mi>
                          </mml:mrow>
                        </mml:mfrac>
                      </mml:mrow>
                    </mml:math>
                  </inline-formula>
                </td>
                <td valign="middle" align="left" rowspan="1" colspan="1">(<xref rid="B6" ref-type="bibr">6</xref>)</td>
              </tr>
              <tr>
                <td valign="middle" align="left" rowspan="1" colspan="1">Accuracy</td>
                <td valign="middle" align="center" rowspan="1" colspan="1">
                  <inline-formula>
                    <mml:math id="im6" display="inline" overflow="scroll">
                      <mml:mrow>
                        <mml:mi>A</mml:mi>
                        <mml:mi>c</mml:mi>
                        <mml:mi>c</mml:mi>
                        <mml:mi>u</mml:mi>
                        <mml:mi>r</mml:mi>
                        <mml:mi>a</mml:mi>
                        <mml:mi>c</mml:mi>
                        <mml:mi>y</mml:mi>
                        <mml:mo>=</mml:mo>
                        <mml:mfrac>
                          <mml:mrow>
                            <mml:mi>T</mml:mi>
                            <mml:mi>P</mml:mi>
                            <mml:mi>K</mml:mi>
                            <mml:mi>O</mml:mi>
                            <mml:mo>+</mml:mo>
                            <mml:mi>T</mml:mi>
                            <mml:mi>N</mml:mi>
                            <mml:mi>K</mml:mi>
                            <mml:mi>O</mml:mi>
                          </mml:mrow>
                          <mml:mrow>
                            <mml:mi>T</mml:mi>
                            <mml:mi>P</mml:mi>
                            <mml:mi>K</mml:mi>
                            <mml:mi>O</mml:mi>
                            <mml:mo>+</mml:mo>
                            <mml:mi>F</mml:mi>
                            <mml:mi>P</mml:mi>
                            <mml:mi>K</mml:mi>
                            <mml:mi>O</mml:mi>
                            <mml:mo>+</mml:mo>
                            <mml:mi>T</mml:mi>
                            <mml:mi>N</mml:mi>
                            <mml:mi>K</mml:mi>
                            <mml:mi>O</mml:mi>
                            <mml:mo>+</mml:mo>
                            <mml:mi>F</mml:mi>
                            <mml:mi>N</mml:mi>
                            <mml:mi>K</mml:mi>
                            <mml:mi>O</mml:mi>
                          </mml:mrow>
                        </mml:mfrac>
                      </mml:mrow>
                    </mml:math>
                  </inline-formula>
                </td>
                <td valign="middle" align="left" rowspan="1" colspan="1">(<xref rid="B7" ref-type="bibr">7</xref>)</td>
              </tr>
              <tr>
                <td valign="middle" align="left" rowspan="1" colspan="1">Precision</td>
                <td valign="middle" align="center" rowspan="1" colspan="1">
                  <inline-formula>
                    <mml:math id="im7" display="inline" overflow="scroll">
                      <mml:mrow>
                        <mml:mi>P</mml:mi>
                        <mml:mi>r</mml:mi>
                        <mml:mi>e</mml:mi>
                        <mml:mi>c</mml:mi>
                        <mml:mi>i</mml:mi>
                        <mml:mi>s</mml:mi>
                        <mml:mi>i</mml:mi>
                        <mml:mi>o</mml:mi>
                        <mml:mi>n</mml:mi>
                        <mml:mo>=</mml:mo>
                        <mml:mfrac>
                          <mml:mrow>
                            <mml:mi>T</mml:mi>
                            <mml:mi>P</mml:mi>
                            <mml:mi>K</mml:mi>
                            <mml:mi>O</mml:mi>
                          </mml:mrow>
                          <mml:mrow>
                            <mml:mi>T</mml:mi>
                            <mml:mi>P</mml:mi>
                            <mml:mi>K</mml:mi>
                            <mml:mi>O</mml:mi>
                            <mml:mo>+</mml:mo>
                            <mml:mi>F</mml:mi>
                            <mml:mi>P</mml:mi>
                            <mml:mi>K</mml:mi>
                            <mml:mi>O</mml:mi>
                          </mml:mrow>
                        </mml:mfrac>
                      </mml:mrow>
                    </mml:math>
                  </inline-formula>
                </td>
                <td valign="middle" align="left" rowspan="1" colspan="1">(<xref rid="B8" ref-type="bibr">8</xref>)</td>
              </tr>
              <tr>
                <td valign="middle" align="left" rowspan="1" colspan="1">Recall</td>
                <td valign="middle" align="center" rowspan="1" colspan="1">
                  <inline-formula>
                    <mml:math id="im8" display="inline" overflow="scroll">
                      <mml:mrow>
                        <mml:mi>R</mml:mi>
                        <mml:mi>e</mml:mi>
                        <mml:mi>c</mml:mi>
                        <mml:mi>a</mml:mi>
                        <mml:mi>l</mml:mi>
                        <mml:mi>l</mml:mi>
                        <mml:mo>=</mml:mo>
                        <mml:mfrac>
                          <mml:mrow>
                            <mml:mi>T</mml:mi>
                            <mml:mi>P</mml:mi>
                            <mml:mi>K</mml:mi>
                            <mml:mi>O</mml:mi>
                          </mml:mrow>
                          <mml:mrow>
                            <mml:mi>T</mml:mi>
                            <mml:mi>P</mml:mi>
                            <mml:mi>K</mml:mi>
                            <mml:mi>O</mml:mi>
                            <mml:mo>+</mml:mo>
                            <mml:mi>F</mml:mi>
                            <mml:mi>N</mml:mi>
                            <mml:mi>K</mml:mi>
                            <mml:mi>O</mml:mi>
                          </mml:mrow>
                        </mml:mfrac>
                      </mml:mrow>
                    </mml:math>
                  </inline-formula>
                </td>
                <td valign="middle" align="left" rowspan="1" colspan="1">(<xref rid="B9" ref-type="bibr">9</xref>)</td>
              </tr>
              <tr>
                <td valign="middle" align="left" rowspan="1" colspan="1"><italic>p</italic>-Threshold</td>
                <td valign="middle" align="left" rowspan="1" colspan="1"><italic>Youden’s_Threshold</italic> = max(<italic>Specificity</italic>+<italic>Sensitivity</italic>)</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">(<xref rid="B10" ref-type="bibr">10</xref>)</td>
              </tr>
              <tr>
                <td valign="middle" align="left" rowspan="1" colspan="1">AUC</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Full area under the entire ROC curve</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">(<xref rid="B11" ref-type="bibr">11</xref>)</td>
              </tr>
              <tr>
                <td valign="middle" align="left" rowspan="1" colspan="1">pAUC_SP</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Partial area for a region of 90–100% specificity</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">(<xref rid="B12" ref-type="bibr">12</xref>)</td>
              </tr>
              <tr>
                <td valign="middle" align="left" rowspan="1" colspan="1">pAUC_SE</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Partial area for a region of 90–100% sensitivity</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">(<xref rid="B13" ref-type="bibr">13</xref>)</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>The principles behind the main module pathwayko (see <xref rid="f1" ref-type="fig"><bold>Figure 1</bold></xref>) are modified from the literature (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B26" ref-type="bibr">26</xref>), as briefly depicted below. (i) By our definition, a true positive KO (TPKO) signaling pathway is a pathway that contains the knockout (KO) gene and was correctly identified to be a significantly impacted by that KO gene (e.g., at the pathway-level <italic>p</italic>-value &lt; 0.001). (ii) A false positive KO (FPKO) signaling pathway is a pathway that does not contain the KO gene, and was not significantly impacted by that KO gene, but was still identified to be significantly impacted. A true negative KO (TNKO) signaling pathway is a pathway that does not contain the KO gene and was not significantly impacted by that KO gene; thus, it was not reported to be significantly impacted. A false negative KO (FNKO) signaling pathway is a pathway that contains the KO gene and was significantly impacted by that KO gene, but was not reported to be significantly impacted. (iii) For such a true-false case, the response versus prediction with a probability allows us to employ the external pROC package (<xref rid="B19" ref-type="bibr">19</xref>) to compute a set of key metrics defined by the above terms (<xref rid="T1" ref-type="table"><bold>Table 1</bold></xref>). (iv) An ROC curve represents the tradeoff between specificity and sensitivity for every possible <italic>p</italic>-value (<xref rid="B19" ref-type="bibr">19</xref>). The Youden’s best <italic>p</italic>-value threshold (denoted as <italic>p</italic>-Threshold) is a <italic>p</italic>-value that defines an optimal point (specificity, sensitivity) on an ROC curve (<xref rid="B26" ref-type="bibr">26</xref>), where the sum of specificity and sensitivity is maximal (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B25" ref-type="bibr">25</xref>). Each point on an ROC curve represents a true KO (both true positive and false negative) signaling pathway in our cases. (v) Some key metrics with local properties (FDR, FPR, FNR, specificity, sensitivity, accuracy, precision and recall) collected at the <italic>p</italic>-threshold (<xref rid="T1" ref-type="table"><bold>Table 1</bold></xref>) can be used to conduct a local comparison; others with global properties (AUC, pAUC_SP and pAUC_SE) can be applied to perform a global comparison. And these key metrics are appropriate for evaluating the performance difference of pathway analysis methods and for assessing the quality of data, both in terms of the ROC curve-based statistics analysis.</p>
      </sec>
    </sec>
    <sec id="s3_3">
      <label>3.3</label>
      <title>Statistics analyzing process</title>
      <sec id="s3_3_1">
        <label>3.3.1</label>
        <title>Feature 4: The two-dimensional probability evidence plots</title>
        <p>The internal evidenceplot module adapted from the SPIA package (<xref rid="B16" ref-type="bibr">16</xref>) can construct the two-dimensional probability evidence plots. The Adj.<italic>p</italic>-value is used to control the false discovery rate (FDR) for multiple testing (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B28" ref-type="bibr">28</xref>). Pathways above the oblique blue (or red) line are significant at 5% after BH-FDR (or Bonferroni) correction of the global <italic>p</italic>-values (<italic>pG</italic>), i.e., an adjusted Fisher’s product of <italic>pPERT</italic> and <italic>pNDE</italic> (<xref rid="B16" ref-type="bibr">16</xref>). Such plots can differentiate each data under comparison after having been analyzed by the SPIA method in view of the resolution along the X- and Y-axes (<xref rid="B16" ref-type="bibr">16</xref>). The highest resolution along the Y-axis, as indicated by the fine distribution, suggests that the most likely target pathways are identified, thus coinciding with its superiority among top-ranked TPKO signaling pathways (e.g., a list of top-30 ranked).</p>
      </sec>
      <sec id="s3_3_2">
        <label>3.3.2</label>
        <title>Feature 5: The ROC curve-based statistical hypothesis testing</title>
        <p>The internal roctest module adapted from the pROC package (<xref rid="B19" ref-type="bibr">19</xref>) can conduct the ROC curve-based statistical hypothesis testing both on the two ROC curves themselves (<italic>via</italic> the venkatraman method) and on the values of AUC, pAUC_SP and pAUC_SE (<italic>via</italic> the bootstrap method). The output files are stored in a new directory (roctest) automatically generated and named after the module.</p>
      </sec>
      <sec id="s3_3_3">
        <label>3.3.3</label>
        <title>Feature 6: The ROC curve-based statistics analysis</title>
        <p>The internal combineresult module can combine individual results of each data across methods, and format them to be a summary output file (STATS.RData). Thereby, the internal violinplot module and the internal wilcoxtest module can conduct the ROC curve-based statistics analysis, comparing the individual key metrics (<xref rid="T1" ref-type="table"><bold>Table 1</bold></xref>) among the methods under comparison. All resulting output files are stored in the respective directories (combineresult, violinplot, and wilcoxtest), which are automatically created and named after the modules.</p>
      </sec>
    </sec>
    <sec id="s3_4">
      <label>3.4</label>
      <title>Visualizing process</title>
      <sec id="s3_4_1">
        <label>3.4.1</label>
        <title>Feature 7: Highlighting target signaling pathways with key regulators</title>
        <p>The internal filtertrue module can extract the signaling pathways, and the internal pathwayview module adapted from the Pathview package (<xref rid="B20" ref-type="bibr">20</xref>) can render them. The resulting output files are stored in the two directories automatically generated and named after the two modules (filtertrue and pathwayview). Key regulators, which are impacted by the same KO gene and are coordinately, significantly up- or down-regulated, can be differentially marked on the target signaling pathways. These rendered signaling pathways illuminate putative mechanisms underlying the KO phenotype at the systems-level.</p>
      </sec>
    </sec>
  </sec>
  <sec id="s4">
    <label>4</label>
    <title>Advanced batch-execution features of the PathwayKO platform</title>
    <sec id="s4_1">
      <label>4.1</label>
      <title>The work-flow logic of utilizing individual modules</title>
      <sec id="s4_1_1">
        <label>4.1.1</label>
        <title>Feature 8: Optional modes for desired tasks</title>
        <p>The work-flow logic of utilizing individual modules of the PathwayKO platform is indicated below (<xref rid="f3" ref-type="fig"><bold>Figure 3</bold></xref>). The modules can be executed in interactive mode or in pipelined batch-execution mode.</p>
        <fig position="float" id="f3">
          <label>Figure 3</label>
          <caption>
            <p>The modes of running individual modules of the PathwayKO platform.</p>
          </caption>
          <graphic xlink:href="fimmu-14-1103392-g003" position="float"/>
        </fig>
      </sec>
    </sec>
    <sec id="s4_2">
      <label>4.2</label>
      <title>Analyzing a collection of data in a pipeline fashion</title>
      <sec id="s4_2_1">
        <label>4.2.1</label>
        <title>Feature 9: All-in-all computations in batch-execution mode</title>
        <p>After a number of data having been preprocessed in a step-by-step manner and stored in the user’s working directory (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Figure S2</bold></xref>), the user may conduct a batch-execution by typing the pathwayko_batch () command within the continued R session (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Figure S3</bold></xref>). This command will start sequential operations: (i) to scan and identify data generated previously by the preprocess module; and (ii) to apply the main pathwayko module to conduct a batch-execution, performing the integrative KO pathway enrichment analysis in a pipeline fashion, both across methods and across data (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Figure S3</bold></xref>).</p>
      </sec>
    </sec>
    <sec id="s4_3">
      <label>4.3</label>
      <title>Evaluating the performance of methods with a benchmark</title>
      <sec id="s4_3_1">
        <label>4.3.1</label>
        <title>Feature 10: Evaluating the performance of methods under the same conditions</title>
        <p>Once a collection of benchmark data have been previously preprocessed and stored in a user’s working directory (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Figure S2</bold></xref>), the user should start a new R session to complete the desired batch-computations by following the offered tutorials, where some key parameters can be initialized in a step-by-step manner (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Figure S3</bold></xref>). All resulting output files should be finally stored in the new directories that are automatically created and named after the modules (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Figure S4</bold></xref>).</p>
      </sec>
    </sec>
  </sec>
  <sec sec-type="results" id="s5">
    <label>5</label>
    <title>Results</title>
    <sec id="s5_1">
      <label>5.1</label>
      <title>Case study 1: Elucidating the mechanisms underlying systems immunology triggered by sterile extensive hepatectomy</title>
      <sec id="s5_1_1">
        <label>5.1.1</label>
        <title>Assignment of transcriptomes reflecting the original bench-experiments</title>
        <p>The original bench-experiments suggested that (i) wild-type (WT) mice had a high mortality rate after sterile 85% liver resection; (ii) single null <italic>Myd88</italic> (<italic>Myd88</italic>
<sup>–/–</sup>) mice had greatly reduced survival rates; (iii) double null <italic>Myd88_ Ager</italic> (<italic>Myd88</italic>
<sup>–/–</sup>
<italic>/Ager</italic>
<sup>–/–</sup>) mice had even more greatly reduced survival rates; but (iv) single null <italic>Ager</italic> (<italic>Ager</italic>
<sup>–/–)</sup> mice had drastically increased survival rates, which suggested opposing roles between MyD88 (encoded by <italic>Myd88</italic>) KO and RAGE (encoded by <italic>Ager</italic>) KO (<xref rid="B3" ref-type="bibr">3</xref>). The GSE22873 GEO data were created from tissues recovered from the remnants of mouse livers 2 hours after the sterile 85% liver resection in the indicated deficient and wild-type mice (<xref rid="B3" ref-type="bibr">3</xref>). These data were not subjected to bioinformatics analysis, similar to our perspectives, although some DEGs and pathways were suggested by primary analyses (<xref rid="B3" ref-type="bibr">3</xref>) with Pathway Express (<xref rid="B16" ref-type="bibr">16</xref>). To investigate the mechanisms underlying such phenomena raised by the original bench-experiments (<xref rid="B3" ref-type="bibr">3</xref>) from the perspective of systems immunology, we applied the PathwayKO platform to analyze the following six subtypes of data we assigned: GSE22873_M (KO <italic>Myd88 vs</italic>. WT), GSE22873_MA (KO <italic>Myd88_Ager vs</italic>. WT), GSE22873_A (KO <italic>Ager vs</italic>. WT), GSE22873_MAvM (KO <italic>Myd88_Ager vs</italic>. KO <italic>Myd88</italic>), GSE22873_MAvA (KO <italic>Myd88_Ager vs</italic>. KO <italic>Ager</italic>) and GSE22873_MvA (KO <italic>Myd88 vs</italic>. KO <italic>Ager</italic>). The results are presented as follows.</p>
      </sec>
      <sec id="s5_1_2">
        <label>5.1.2</label>
        <title>The distribution of edge scores automatically estimated from a global graph</title>
        <p>The distribution of edge scores varied drastically among data (<xref rid="f4" ref-type="fig"><bold>Figure 4</bold></xref>). Each showed a distinction, as marked by an HES threshold (HES1, HES2 and HES3, respectively), and reflected the different effects of experimental treatments.</p>
        <fig position="float" id="f4">
          <label>Figure 4</label>
          <caption>
            <p>The distribution of edge scores with drastic variations among data. <bold>(A)</bold> GSE22873_M; <bold>(B)</bold> GSE22873_MA; <bold>(C)</bold> GSE22873_A; <bold>(D)</bold> GSE22873_MAvM; <bold>(E)</bold> GSE22873_MAvA; <bold>(F)</bold> GSE22873_MvA.</p>
          </caption>
          <graphic xlink:href="fimmu-14-1103392-g004" position="float"/>
        </fig>
      </sec>
      <sec id="s5_1_3">
        <label>5.1.3</label>
        <title>The differentially expressed genes statistically selected by an HES threshold</title>
        <p>DEGs were statistically selected by using an HES threshold, as described in Methods (see <xref rid="f2" ref-type="fig"><bold>Figures 2</bold></xref>, <xref rid="f4" ref-type="fig"><bold>4</bold></xref>). By the HES1, HES2 and HES3 thresholds, respectively, GSE22873_M separately had 122 DEGs, 38 DEGs and 2 DEGs (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Table S1</bold></xref>) with the top 10-ranked genes (<italic>Myd88</italic>, <italic>Cxcl1</italic>, <italic>Fos</italic>, <italic>Nfatc3</italic>, <italic>Ccr1l1</italic>, <italic>Cxcr2</italic>, <italic>Ccr4</italic>, <italic>Rela</italic>, <italic>Jun</italic> and <italic>Xcr1</italic>); GSE22873_MA had 130 DEGs, 57 DEGs and 2 DEGs (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Table S2</bold></xref>) with the top 10-ranked genes (<italic>Myd88</italic>, <italic>Cxcl1</italic>, <italic>H2-Bl</italic>, <italic>Ccr1l1</italic>, <italic>Ccr10</italic>, <italic>Cxcr2</italic>, <italic>Rela</italic>, <italic>Xcr1</italic>, <italic>Ccr1</italic> and <italic>Cxcr5</italic>); and GSE22873_A had 135 DEGs, 27 DEGs and 2 DEGs (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Table S3</bold></xref>) with the top 10-ranked genes (<italic>H2-Bl</italic>, <italic>H2-T24</italic>, <italic>H2-M3</italic>, <italic>H2-Q6</italic>, <italic>Cdkn1a</italic>, <italic>Tapbp</italic>, <italic>AP1g1</italic>, <italic>Ap1b1</italic>, <italic>Ap1m1</italic> and <italic>H2-M10.1</italic>). Similarly, by the HES1 threshold, there were 55 DEGs (with top-ranked <italic>H2-Bl</italic> and <italic>H2-T24</italic>) in GSE22873_MAvM (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Table S4</bold></xref>); 67 DEGs (with top-ranked <italic>Myd88</italic> and <italic>Cxcl1</italic>) in GSE22873_MAvA (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Table S5</bold></xref>); and 347 GEGs (with top-ranked <italic>H2-Bl, H2-M10.1, Myd88</italic> and <italic>Cxcl1</italic>) in GSE22873_MvA (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Table S6</bold></xref>). Of note, rather than <italic>Ager</italic> itself, the MHC/antigen-related genes were ranked in the top 10 in GSE22873_A, which compared RAGE-null with wild-type mice. None of the above lists contained <italic>Ager</italic>, suggesting that (i) <italic>Ager</italic> itself was not yet significantly differentially expressed as early as 2 hours post-surgery when comparing RAGE-null against wild-type mice in GSE22873_A (KO <italic>Ager vs</italic>. WT), born by the transcriptome, in our current analysis; and (ii) RAGE (<italic>Ager</italic>)-mediated MHC/antigen-related genes play the most important roles, implying epigenetic effects.</p>
      </sec>
      <sec id="s5_1_4">
        <label>5.1.4</label>
        <title>The KO gene-associated subnetwork automatically constructed from DEGs</title>
        <p>The KO gene-associated subnetwork was comprised of the statistically selected DEGs (<xref rid="f5" ref-type="fig"><bold>Figure 5</bold></xref>). The landscapes of these subnetworks explicitly revealed the global effects of experimental treatments at the systems-level. For instance, the top-ranked two genes (<italic>Myd88</italic> and <italic>Cxcl1</italic>) connected the last edge, as highlighted by the HES3 threshold (see <xref rid="f4" ref-type="fig"><bold>Figure 4</bold></xref>); this result suggests that the KO <italic>Myd88</italic>-signaling stimulated the highest responsive expression of <italic>Cxcl1</italic> in both GSE22873_M (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Table S1</bold></xref>) and GSE22873_MA (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Table S2</bold></xref>). Similarly, the top-ranked two genes (<italic>H2-Bl</italic> and <italic>H2-T24</italic>) connected the last edge (see <xref rid="f4" ref-type="fig"><bold>Figure 4</bold></xref>), suggesting that the KO <italic>Ager</italic>-signaling stimulated the highest responsive expression of <italic>H2-Bl</italic> and <italic>H2-T24</italic> in GSE22873_A (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Table S3</bold></xref>). In addition, the remaining pairs displayed drastic variations, reflecting subtractive responses between the indicated pairs (<xref rid="f5" ref-type="fig"><bold>Figure 5</bold></xref>).</p>
        <fig position="float" id="f5">
          <label>Figure 5</label>
          <caption>
            <p>The KO gene-associated subnetworks comprised of DEGs statistically determined by HES1 and HES2. Landscapes are displayed since many node labels are unreadable by humans. Representative key nodes (e.g., Myd88, Cxcl1 and H2-Bl) are enlarged for clarity. <bold>(A)</bold> GSE22873_M, <bold>(B)</bold> GSE22873_MA, and <bold>(C)</bold> GSE22873_A at HES1; <bold>(D)</bold> GSE22873_M, <bold>(E)</bold> GSE22873_MA, and <bold>(F)</bold> GSE22873_A at HES2; <bold>(G)</bold> GSE22873_MAvM, <bold>(H)</bold> GSE22873_MAvA, and <bold>(I)</bold> GSE22873_MvA at HES1.</p>
          </caption>
          <graphic xlink:href="fimmu-14-1103392-g005" position="float"/>
        </fig>
      </sec>
      <sec id="s5_1_5">
        <label>5.1.5</label>
        <title>The ROC curves with statistical features automatically built in a pipeline fashion</title>
        <p>The ROC curves with statistical features (<xref rid="f6" ref-type="fig"><bold>Figure 6</bold></xref>) were generated in a pipeline fashion, both across methods and across data. These results indicate the diverse landscapes of experimental treatments (data), which can discriminate the performance difference of pathway analysis methods under comparison. (i) An AUC with 95% CI and Youden’s best <italic>p</italic>-value threshold (noted shortly as <italic>p</italic>-Threshold) were marked on each ROC curve, indicating an optimal point (specificity, sensitivity) for a method. (ii) The 95% CIs of both specificity and sensitivity were marked on each ROC curve, indicating the deviation for a method on one data point. For instance, the drastic variation in 95% CIs shown in GSE22873_A (KO <italic>Ager vs</italic>. WT) data suggested weak signals over noise, which might impact the statistical hypothesis testing (<xref rid="B19" ref-type="bibr">19</xref>). (iii) The partial AUCs (pAUC_SP and pAUC_SE) of 90–100% specificity and sensitivity were marked on each ROC curve, implying a bias toward a higher specificity and sensitivity, respectively. (iv) The multiple ROC curves with AUCs intuitively displayed the superiority of methods when benchmarked on the same data (<xref rid="f6" ref-type="fig"><bold>Figure 6</bold></xref>).</p>
        <fig position="float" id="f6">
          <label>Figure 6</label>
          <caption>
            <p>ROC curves with statistical features. GSE22873_A (KO <italic>Ager</italic> vs. WT) displays a weak signal to noise ratio, implying a lower degree of response to the stimulus. <bold>(A)</bold> GSE22873_M; <bold>(B)</bold> GSE22873_MA; <bold>(C)</bold> GSE22873_A.</p>
          </caption>
          <graphic xlink:href="fimmu-14-1103392-g006" position="float"/>
        </fig>
      </sec>
      <sec id="s5_1_6">
        <label>5.1.6</label>
        <title>The ROC curve-based statistical hypothesis testing based on key metrics</title>
        <p>The ROC curve-based statistical hypothesis testing was conducted to indicate the significance level of the difference between the two methods (<xref rid="f7" ref-type="fig"><bold>Figure 7</bold></xref>). For instance, two methods (SPIA <italic>vs</italic>. GSEA) had a significant difference (e.g., <italic>p</italic>-value &lt; 0.05) when benchmarked on GSE22873_M and GSE22873_MA, respectively, in view of both ROC curves themselves (<italic>via</italic> the venkatraman method) and the values of AUC, pAUC_SP and pAUC_SE (<italic>via</italic> the bootstrap method). SPIA was better than GSEA in these two cases (<xref rid="f7" ref-type="fig"><bold>Figures 7A, B</bold></xref>). However, the same two methods (SPIA <italic>vs</italic>. GSEA) showed no significant difference (e.g., <italic>p</italic>-value &gt; 0.1) when benchmarked on GSE22873_A (<xref rid="f7" ref-type="fig"><bold>Figure 7C</bold></xref>). The reason is likely attributed to the drastic variations in the 95% CIs of specificity and sensitivity in GSE22873_A (see <xref rid="f6" ref-type="fig"><bold>Figure 6C</bold></xref>), which impact the resampling-based bootstrap assessments used for the ROC curves-based statistical hypothesis testing (<xref rid="B19" ref-type="bibr">19</xref>).</p>
        <fig position="float" id="f7">
          <label>Figure 7</label>
          <caption>
            <p>ROC curves-based statistical hypothesis testing of key metrics. The top-panel is testing the two ROC curves themselves (<italic>via</italic> the venkatraman method). The remaining panels are testing the AUC, pAUC_SP and pAUC_SE values (<italic>via</italic> the bootstrap method). <bold>(A)</bold> GSE22873_M; <bold>(B)</bold> GSE22873_MA; <bold>(C)</bold> GSE22873_A.</p>
          </caption>
          <graphic xlink:href="fimmu-14-1103392-g007" position="float"/>
        </fig>
      </sec>
      <sec id="s5_1_7">
        <label>5.1.7</label>
        <title>The two-dimensional probability evidence plots</title>
        <p>The two-dimensional probability evidence plots were created for six data (<xref rid="f8" ref-type="fig"><bold>Figure 8</bold></xref>), which discriminate these data in view of the resolution along the X- and Y-axes. The highest resolution along the Y-axis suggests that the most likely target pathways were identified by SPIA, as indicated by the fine distribution.</p>
        <fig position="float" id="f8">
          <label>Figure 8</label>
          <caption>
            <p>Two-dimensional probability evidence plots. A randomly assigned signaling pathway (green dot) located above or below the lines of significance level suggests the intuitive difference in fine distributions among data. <bold>(A)</bold> GSE22873_M; <bold>(B)</bold> GSE22873_MA; <bold>(C)</bold> GSE22873_A; <bold>(D)</bold> GSE22873_MAvM; <bold>(E)</bold> GSE22873_MAvA; <bold>(F)</bold> GSE22873_MvA.</p>
          </caption>
          <graphic xlink:href="fimmu-14-1103392-g008" position="float"/>
        </fig>
      </sec>
      <sec id="s5_1_8">
        <label>5.1.8</label>
        <title>The true positive knockout signaling pathways statistically identified</title>
        <p>We identified diverse true KO signaling pathways, which contained target KO gene(s), including 21 from GSE22873_M (KO <italic>Myd88 vs</italic>. WT), 23 from GSE22873_MA (KO <italic>Myd88</italic>_ <italic>Ager vs</italic>. WT), 3 from GSE22873_A (KO <italic>Ager vs</italic>. WT) and 24 from GSE22873_MvA (KO <italic>Myd88 vs</italic>. KO <italic>Ager</italic>) (<xref rid="T2" ref-type="table"><bold>Table 2</bold></xref>; <xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Table S7</bold></xref>). The majority of them were identified to be TPKO signaling pathways at a statistical significance level (e.g., pGFdr &lt; 0.001 or 0.005) by our definitions described in Methods. (i) All 21 pathways from GSE22873_M were TPKO signaling pathways. (ii) Twenty-two out of 23 pathways were TPKO signaling pathways, whereas only 1 (mmu05010: Alzheimer disease) out of 23 pathways from GSE22873_MA was a false negative knockout (FNKO) signaling pathway; i.e., this pathway contained a target KO gene and should have been significantly impacted, but was not identified to be positive at a significance level (pGFdr &gt; 0.005). (iii) Only 1 (mmu04933: AGE-RAGE signaling pathway in diabetic complications) out of 3 pathways from GSE22873_A was a TPKO signaling pathway, whereas the remaining two pathways were FNKO signaling pathways (pGFdr &gt; 0.005). (iv) Twenty-three out of 24 pathways from GSE22873_MvA were TPKO signaling pathways, whereas only 1 (mmu05150: Staphylococcus aureus infection) out of 24 pathways was an FNKO signaling pathway (pGFdr &gt; 0.005) (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Table S7</bold></xref>).</p>
        <table-wrap position="float" id="T2">
          <label>Table 2</label>
          <caption>
            <p>True KO signaling pathways identified by SPIA from GSE22873.</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th valign="middle" align="left" rowspan="1" colspan="1">Order</th>
                <th valign="middle" align="left" rowspan="1" colspan="1">Pathway ID</th>
                <th valign="middle" align="left" rowspan="1" colspan="1">Pathway Name</th>
                <th valign="top" align="right" rowspan="1" colspan="1">Status</th>
                <th valign="top" align="right" rowspan="1" colspan="1">pSize</th>
                <th valign="top" align="right" rowspan="1" colspan="1">DEGs (%)</th>
                <th valign="top" colspan="2" align="right" rowspan="1">pGFdr</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <th valign="middle" colspan="8" align="left" rowspan="1">Pathways identified from GSE22873_M (KO <italic>Myd88 vs.</italic> WT)</th>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">
                  <bold>1</bold>
                </td>
                <td valign="middle" align="right" rowspan="1" colspan="1">
                  <bold>mmu04620</bold>
                </td>
                <td valign="middle" align="left" rowspan="1" colspan="1">
                  <bold>Toll-like receptor signaling pathway</bold>
                </td>
                <td valign="top" align="right" rowspan="1" colspan="1">
                  <bold>Inhibited</bold>
                </td>
                <td valign="top" align="right" rowspan="1" colspan="1">
                  <bold>87</bold>
                </td>
                <td valign="top" align="right" rowspan="1" colspan="1">
                  <bold>36 (41.38)</bold>
                </td>
                <td valign="middle" colspan="2" align="right" rowspan="1">
                  <bold>1.03E-33</bold>
                </td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">2</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05161</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Hepatitis B</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">149</td>
                <td valign="top" align="right" rowspan="1" colspan="1">36 (24.16)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">1.20E-24</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">3</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05140</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Leishmaniasis</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">66</td>
                <td valign="top" align="right" rowspan="1" colspan="1">23 (34.85)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">9.51E-20</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">4</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05152</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Tuberculosis</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">158</td>
                <td valign="top" align="right" rowspan="1" colspan="1">32 (20.25)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">2.20E-19</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">5</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu04621</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">NOD-like receptor signaling pathway</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">148</td>
                <td valign="top" align="right" rowspan="1" colspan="1">30 (20.27)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">6.91E-18</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">6</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05162</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Measles</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">131</td>
                <td valign="top" align="right" rowspan="1" colspan="1">28 (21.37)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">6.91E-18</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">7</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05142</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Chagas disease (American trypanosomiasis)</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">99</td>
                <td valign="top" align="right" rowspan="1" colspan="1">23 (23.23)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">4.43E-15</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">8</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05169</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Epstein-Barr virus infection</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">185</td>
                <td valign="top" align="right" rowspan="1" colspan="1">29 (15.68)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">1.16E-14</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">9</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05164</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Influenza A</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">143</td>
                <td valign="top" align="right" rowspan="1" colspan="1">26 (18.18)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">1.40E-14</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">10</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05145</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Toxoplasmosis</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">105</td>
                <td valign="top" align="right" rowspan="1" colspan="1">22 (20.95)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">2.62E-14</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">11</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05170</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Human immunodeficiency virus 1 infection</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">194</td>
                <td valign="top" align="right" rowspan="1" colspan="1">28 (14.43)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">2.16E-13</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">12</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05135</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Yersinia infection</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">116</td>
                <td valign="top" align="right" rowspan="1" colspan="1">22 (18.97)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">7.84E-13</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">13</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05133</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Pertussis</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">67</td>
                <td valign="top" align="right" rowspan="1" colspan="1">17 (25.37)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">2.36E-12</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">14</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu04064</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">NF-kappa B signaling pathway</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">92</td>
                <td valign="top" align="right" rowspan="1" colspan="1">18 (19.57)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">1.94E-10</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">15</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05168</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Herpes simplex virus 1 infection</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">340</td>
                <td valign="top" align="right" rowspan="1" colspan="1">31 (9.12)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">3.64E-10</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">16</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05132</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Salmonella infection</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">193</td>
                <td valign="top" align="right" rowspan="1" colspan="1">24 (12.44)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">5.73E-10</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">17</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05134</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Legionellosis</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">51</td>
                <td valign="top" align="right" rowspan="1" colspan="1">13 (25.49)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">2.56E-09</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">18</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05235</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">PD-L1/PD-1 checkpoint pathway in cancer</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">84</td>
                <td valign="top" align="right" rowspan="1" colspan="1">15 (17.86)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">1.38E-08</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">19</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu04010</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">MAPK signaling pathway</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">281</td>
                <td valign="top" align="right" rowspan="1" colspan="1">25 (8.90)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">3.65E-07</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">20</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05144</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Malaria</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">48</td>
                <td valign="top" align="right" rowspan="1" colspan="1">9 (18.75)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">1.23E-05</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">21</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05143</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">African trypanosomiasis</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">31</td>
                <td valign="top" align="right" rowspan="1" colspan="1">7 (22.58)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">0.000126</td>
              </tr>
              <tr>
                <th valign="middle" colspan="8" align="left" rowspan="1">Pathways identified from GSE22873_MA (KO <italic>Myd88</italic>_<italic>Ager vs.</italic> WT)</th>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">1</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05170</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Human immunodeficiency virus 1 infection</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">194</td>
                <td valign="top" align="right" rowspan="1" colspan="1">61 (31.44)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">2.18E-50</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">
                  <bold>2</bold>
                </td>
                <td valign="middle" align="right" rowspan="1" colspan="1">
                  <bold>mmu04620</bold>
                </td>
                <td valign="middle" align="left" rowspan="1" colspan="1">
                  <bold>Toll-like receptor signaling pathway</bold>
                </td>
                <td valign="top" align="right" rowspan="1" colspan="1">
                  <bold>Inhibited</bold>
                </td>
                <td valign="top" align="right" rowspan="1" colspan="1">
                  <bold>87</bold>
                </td>
                <td valign="top" align="right" rowspan="1" colspan="1">
                  <bold>44 (50.57)</bold>
                </td>
                <td valign="middle" colspan="2" align="right" rowspan="1">
                  <bold>1.24E-45</bold>
                </td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">3</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05169</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Epstein-Barr virus infection</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Activated</td>
                <td valign="top" align="right" rowspan="1" colspan="1">185</td>
                <td valign="top" align="right" rowspan="1" colspan="1">53 (28.65)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">8.65E-41</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">4</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05142</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Chagas disease (American trypanosomiasis)</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">99</td>
                <td valign="top" align="right" rowspan="1" colspan="1">35 (35.35)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">2.30E-29</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">5</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05162</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Measles</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">131</td>
                <td valign="top" align="right" rowspan="1" colspan="1">38 (29.01)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">1.42E-28</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">6</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05161</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Hepatitis B</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">149</td>
                <td valign="top" align="right" rowspan="1" colspan="1">40 (26.85)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">1.63E-28</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">7</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05135</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Yersinia infection</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">116</td>
                <td valign="top" align="right" rowspan="1" colspan="1">35 (30.17)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">1.61E-26</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">8</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05235</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">PD-L1/PD-1 checkpoint pathway in cancer</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">84</td>
                <td valign="top" align="right" rowspan="1" colspan="1">31 (36.91)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">1.94E-26</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">9</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05168</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Herpes simplex virus 1 infection</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">340</td>
                <td valign="top" align="right" rowspan="1" colspan="1">50 (14.71)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">6.55E-24</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">10</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu04621</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">NOD-like receptor signaling pathway</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Activated</td>
                <td valign="top" align="right" rowspan="1" colspan="1">148</td>
                <td valign="top" align="right" rowspan="1" colspan="1">33 (22.30)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">1.24E-20</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">11</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05140</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Leishmaniasis</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">66</td>
                <td valign="top" align="right" rowspan="1" colspan="1">23 (34.85)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">3.92E-19</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">12</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05164</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Influenza A</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">143</td>
                <td valign="top" align="right" rowspan="1" colspan="1">31 (21.68)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">7.33E-19</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">13</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05152</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Tuberculosis</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">158</td>
                <td valign="top" align="right" rowspan="1" colspan="1">31 (19.62)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">1.74E-17</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">14</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05133</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Pertussis</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">67</td>
                <td valign="top" align="right" rowspan="1" colspan="1">21 (31.34)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">2.00E-16</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">15</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05145</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Toxoplasmosis</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">105</td>
                <td valign="top" align="right" rowspan="1" colspan="1">23 (21.91)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">1.60E-14</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">16</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu04064</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">NF-kappa B signaling pathway</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">92</td>
                <td valign="top" align="right" rowspan="1" colspan="1">22 (23.91)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">5.09E-14</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">17</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05132</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Salmonella infection</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">193</td>
                <td valign="top" align="right" rowspan="1" colspan="1">26 (13.47)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">5.18E-11</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">
                  <bold>18</bold>
                </td>
                <td valign="middle" align="right" rowspan="1" colspan="1">
                  <bold>mmu04933</bold>
                </td>
                <td valign="middle" align="left" rowspan="1" colspan="1">
                  <bold>AGE-RAGE signaling pathway in diabetics</bold>
                </td>
                <td valign="top" align="right" rowspan="1" colspan="1">
                  <bold>Activated</bold>
                </td>
                <td valign="top" align="right" rowspan="1" colspan="1">
                  <bold>98</bold>
                </td>
                <td valign="top" align="right" rowspan="1" colspan="1">
                  <bold>18 (18.37)</bold>
                </td>
                <td valign="middle" colspan="2" align="right" rowspan="1">
                  <bold>1.58E-09</bold>
                </td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">19</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05134</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Legionellosis</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">51</td>
                <td valign="top" align="right" rowspan="1" colspan="1">13 (25.49)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">7.03E-09</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">20</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu04010</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">MAPK signaling pathway</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">281</td>
                <td valign="top" align="right" rowspan="1" colspan="1">22 (7.83)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">6.66E-06</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">21</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05144</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Malaria</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">48</td>
                <td valign="top" align="right" rowspan="1" colspan="1">9 (18.75)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">2.00E-05</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">22</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05143</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">African trypanosomiasis</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Inhibited</td>
                <td valign="top" align="right" rowspan="1" colspan="1">31</td>
                <td valign="top" align="right" rowspan="1" colspan="1">7 (22.58)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">0.000149</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">23</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05010</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Alzheimer disease</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Activated</td>
                <td valign="top" align="right" rowspan="1" colspan="1">311</td>
                <td valign="top" align="right" rowspan="1" colspan="1">13 (4.18)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">0.158326</td>
              </tr>
              <tr>
                <th valign="middle" colspan="8" align="left" rowspan="1">Pathways identified from GSE22873_A (KO <italic>Ager vs.</italic> WT)</th>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">
                  <bold>1</bold>
                </td>
                <td valign="middle" align="right" rowspan="1" colspan="1">
                  <bold>mmu04933</bold>
                </td>
                <td valign="middle" align="left" rowspan="1" colspan="1">
                  <bold>AGE-RAGE signaling pathway in diabetics</bold>
                </td>
                <td valign="top" align="right" rowspan="1" colspan="1">
                  <bold>Activated</bold>
                </td>
                <td valign="top" align="right" rowspan="1" colspan="1">
                  <bold>98</bold>
                </td>
                <td valign="top" align="right" rowspan="1" colspan="1">
                  <bold>10 (10.20)</bold>
                </td>
                <td valign="middle" colspan="2" align="right" rowspan="1">
                  <bold>0.002314</bold>
                </td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">2</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05150</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Staphylococcus aureus infection</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Activated</td>
                <td valign="top" align="right" rowspan="1" colspan="1">76</td>
                <td valign="top" align="right" rowspan="1" colspan="1">3 (3.95)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">0.476408</td>
              </tr>
              <tr>
                <td valign="middle" align="right" rowspan="1" colspan="1">3</td>
                <td valign="middle" align="right" rowspan="1" colspan="1">mmu05010</td>
                <td valign="middle" align="left" rowspan="1" colspan="1">Alzheimer disease</td>
                <td valign="top" align="right" rowspan="1" colspan="1">Activated</td>
                <td valign="top" align="right" rowspan="1" colspan="1">311</td>
                <td valign="top" align="right" rowspan="1" colspan="1">8 (2.57)</td>
                <td valign="middle" colspan="2" align="right" rowspan="1">0.638874</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>True positive knockout (TPKO) signaling pathway (pGFdr &lt; 0.001 or 0.005) and false negative knockout (FNKO) signaling pathway (pGFdr &gt; 0.005) are distinguishable. Bold pathways are discussed in the main text.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>We categorized target TPKO signaling pathways into the following two groups (<xref rid="B1" ref-type="bibr">1</xref>): the basal signaling pathway that is solely responsible for the KO-gene phenotype; and the composite signaling pathway that embeds the named basal signaling pathway. Here, the basal signaling pathway for KO <italic>Myd88</italic> was the Toll-like receptor signaling pathway (mmu04620), while the composite signaling pathways were the remaining <italic>Myd88</italic>-containing signaling pathways (<xref rid="T2" ref-type="table"><bold>Table 2</bold></xref>; <xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Table S7</bold></xref>). Similarly, the basal signaling pathway for KO <italic>Ager</italic> was the AGE-RAGE signaling pathway in diabetic complications (mmu04933), while the composite signaling pathways were the remaining <italic>Ager</italic>-containing pathways (<xref rid="T2" ref-type="table"><bold>Table 2</bold></xref>; <xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Table S7</bold></xref>). Diverse target TPKO signaling pathways were mainly linked to innate inflammatory responses.</p>
      </sec>
      <sec id="s5_1_9">
        <label>5.1.9</label>
        <title>The target TPKO signaling pathways highlighted at the systems-level</title>
        <p>The target TPKO signaling pathways identified by the SPIA method (see <xref rid="T2" ref-type="table"><bold>Table 2</bold></xref>; <xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Table S7</bold></xref>) were rendered with key regulatory proteins (encoded by <italic>genes</italic>). Key regulators included ligands, receptors, adapters, transducers, transcription factors and cytokines, which were coordinately, significantly and differentially expressed at the systems-level. Such key regulators may constitute a signaling-axis, as marked on a target TPKO signaling pathway. Some top-ranked target TPKO signaling pathways are highlighted below as examples (<xref rid="f9" ref-type="fig"><bold>Figures 9</bold></xref>–<xref rid="f11" ref-type="fig"><bold>11</bold></xref>).</p>
        <fig position="float" id="f9">
          <label>Figure 9</label>
          <caption>
            <p>Comparison of the rendered Toll-like receptor signaling pathway (mmu04620) identified by the SPIA method. This target basal TPKO signaling pathway is solely responsible for the <italic>Myd88</italic>-null phenotype and is significantly inhibited in deficient mice compared to wild-type mice. The opposing roles of the <bold>(A)</bold> single <italic>Myd88</italic>-null and <bold>(B)</bold> double <italic>Myd88_Ager</italic>-null mutants highlight the global effects of key regulators (e.g., MyD88, NFκB, AP1 and cytokines) on orchestrating innate inflammatory responses at the systems-level. Treatment <bold>(C)</bold> reflects the subtractive difference between treatments <bold>(A, B)</bold>. <bold>(A)</bold> GSE22873_M; <bold>(B)</bold> GSE22873_MA; <bold>(C)</bold> GSE22873_MAvM.</p>
          </caption>
          <graphic xlink:href="fimmu-14-1103392-g009" position="float"/>
        </fig>
        <fig position="float" id="f10">
          <label>Figure 10</label>
          <caption>
            <p>Comparison of the rendered AGE-RAGE signaling pathway in diabetic complications (mmu04933) identified by the SPIA method. This target basal TPKO signaling pathway is solely responsible for the Ager-null (KO RAGE) phenotype, and is significantly activated in deficient mice compared to wild-type mice as early as 2 hours post-surgery. The opposing roles of the <bold>(A)</bold> double Myd88_ Ager-null and <bold>(B)</bold> single Ager-null mutants highlight the global effects of key regulators (e.g., NFkB, MCP1 and PIM1) on orchestrating innate inflammatory responses at the systems-level. Treatment <bold>(C)</bold> reflects the subtractive difference between treatments <bold>(A, B)</bold>. <bold>(A)</bold> GSE22873_MA; <bold>(B)</bold> GSE22873_A; <bold>(C)</bold> GSE22873_MAvA.</p>
          </caption>
          <graphic xlink:href="fimmu-14-1103392-g010" position="float"/>
        </fig>
        <sec id="s5_1_9_1">
          <label>5.1.9.1</label>
          <title>Scenario 1</title>
          <p>The Toll-like receptor signaling pathway (mmu04620) was the target basal signaling pathway that was solely responsible for the <italic>Myd88</italic>-null phenotype in both single <italic>Myd88</italic>-null and double <italic>Myd88_Ager</italic>-null mutants (<xref rid="f9" ref-type="fig"><bold>Figure 9</bold></xref>). This pathway was significantly inhibited in deficient mice compared to wild-type mice (see <xref rid="T2" ref-type="table"><bold>Table 2</bold></xref>; <xref rid="f9" ref-type="fig"><bold>Figure 9</bold></xref>). More than 40% of its 87 critical genes were DEGs that were coordinately, significantly and differentially up- or down-regulated as early as 2 hours post-surgery (see <xref rid="T2" ref-type="table"><bold>Table 2</bold></xref>). The opposing roles of single <italic>Myd88</italic>-null and double <italic>Myd88_Ager</italic>-null mutants highlighted the global effects of key regulators (MyD88, NFκB, AP1 (FOS, JUN) and cytokines) on orchestrating innate inflammatory responses at the systems-level. (i) Key regulators in GSE22873_M (<xref rid="f9" ref-type="fig"><bold>Figure 9A</bold></xref>) included significantly down-regulated TLR2, MyD88 and p38 as well as significantly up-regulated TAB2, IRF7 and AP1 (FOS, JUN). These regulators were part of the TLR2-MyD88-TABs-AP1-ILs/CCL axis, which orchestrated the significant down-regulation of downstream inflammatory cytokines (TNFα, IL6, IL12, RANTES (CCL5), IFNβ and IP10 (CXCL10)), and reduced the proinflammatory, anti-viral and chemotactic effects at the systems-level. (ii) Key regulators in GSE22873_MA (<xref rid="f9" ref-type="fig"><bold>Figure 9B</bold></xref>) included significantly down-regulated MyD88, PI3K and IP10 (CXCL10) as well as significantly up-regulated FADD, AKT, NFκB and IRF7. Such regulators constituted the TLRs-MyD88-IRAKs-TABs-NFκB axis, the TLRs-PI3K-AKT-NFκB axis, the TLRs-MyD88-IRAKs-IRF7 axis, and the TLRs-MyD88-FADD-CASP8 axis. Most of these axes regulated the expression of inflammatory cytokines and induced proinflammatory and chemotactic effects. In addition, the TLRs-MyD88-FADD-CASP8 axis promoted apoptosis. (iii) The subtractive difference between the single <italic>Myd88</italic>-null and double <italic>Myd88</italic>_<italic>Ager</italic>-null mutants (<xref rid="f9" ref-type="fig"><bold>Figures 9A, B</bold></xref>) is displayed in <xref rid="f9" ref-type="fig"><bold>Figure 9C</bold></xref>. <italic>Ager</italic>-null mice, backgrounded in <italic>Myd88</italic>-null, induced down-regulation of PI3K and AP1 (FOS, JUN), but up-regulation of IRF5, IL6 and MIP-1α (CCL3); these factors further regulated the proinflammatory and chemotactic effects.</p>
        </sec>
        <sec id="s5_1_9_2">
          <label>5.1.9.2</label>
          <title>Scenario 2</title>
          <p>The AGE-RAGE signaling pathway in diabetic complications (mmu04933) was the target basal signaling pathway that was solely responsible for the <italic>Ager</italic>-null phenotype in both single <italic>Ager</italic>-null and double <italic>Myd88</italic>_<italic>Ager</italic>-null mutants (<xref rid="f10" ref-type="fig"><bold>Figure 10</bold></xref>). This pathway was significantly activated in the indicated deficient mice compared to wild-type mice (see <xref rid="T2" ref-type="table"><bold>Table 2</bold></xref>; <xref rid="f10" ref-type="fig"><bold>Figure 10</bold></xref>). Less than 20% of its 98 critical genes were DEGs that were coordinately, significantly and differentially up- or down-regulated as early as 2 hours post-hepatectomy in the two treatments (see <xref rid="T2" ref-type="table"><bold>Table 2</bold></xref>). The opposing roles of the single <italic>Ager</italic>-null and double <italic>Myd88_ Ager</italic>-null mutants highlighted the global effects of key regulators (NFκB, PIM1 and MCP1 (CCL2 and CCL12)) on orchestrating innate inflammatory responses at the systems-level. (i) Key regulators in GSE22873_MA (<xref rid="f11" ref-type="fig"><bold>Figure 10A</bold></xref>) included significantly down-regulated PI3K as well as significantly up-regulated AKT and NFκB, which were part of the AGEs-RAGE-PI3K-AKT-NFκB-MCP1 axis of the embedded PI3K-AKT signaling pathway (mmu04151). Activation of this axis determined the significant down-regulation of downstream inflammatory cytokine MCP1 (CCL2 and CCL12), thereby reduced the inflammation, atherosclerosis and thrombogenesis effects at the systems-level. (ii) Key regulators in GSE22873_A (<xref rid="f10" ref-type="fig"><bold>Figure 10B</bold></xref>) constituted multiple axes involved in regulating the single <italic>Ager</italic>-null phenotype. Firstly, key regulators included significantly down-regulated PLC and significantly up-regulated NFκB, and were part of the AGEs-RAGE-PLC-PKC-NFκB axis. Activation of this axis, coupled with the embedded MAPK signaling pathway (mmu04010) and the calcium signaling pathway (mmu04020), induced inflammation, atherosclerosis and thrombogenesis, in addition to RAGE-mediated positive feedback. Secondly, key regulators including significantly up-regulated STAT5 and PIM1 were part of the AGEs-RAGE-JAK2-STAT3-PIM1 axis. This axis, coupled with the embedded JAK-STAT signaling pathway (mmu04630), regulated vascular remodeling. Alternatively, the AGEs-RAGE-JAK2-STAT5-CycD1/CDK4 axis, coupled with the cell cycle signaling pathway, regulated cellular proliferation, leading to renal hypertrophy. Finally, the key regulator AT1R was significantly up-regulated and part of the AGT-AT1R-TGFβ-TGFβR-SMADs-p27/ECM axis. This axis, coupled with the embedded TGFβ signaling pathway (mmu04350), regulated cell hypertrophy and mesangial matrix expansion. Strikingly, RAGE (encoded by <italic>Ager</italic>) itself was not significantly up- or down-regulated in both cases when comparing the indicated null mutants against wild-type mice as early as 2 hours post-surgery in our current analysis, which implies that RAGE likely has an indirect effect of unclear epigenetics on regulating the single <italic>Ager</italic>-null (KO RAGE) phenotype at the systems-level. In addition, the subtractive difference between the two cases (<xref rid="f10" ref-type="fig"><bold>Figures 10A, B</bold></xref>) is displayed in <xref rid="f10" ref-type="fig"><bold>Figure 10C</bold></xref>. <italic>Myd88</italic>-null mice, backgrounded in <italic>Ager</italic>-null, induced down-regulation of PI3K, AP1 (FOS, JUN) and NFκB, but up-regulation of p21RAS, which further up-regulated the production of IL6, which is responsible for inflammation.</p>
          <fig position="float" id="f11">
            <label>Figure 11</label>
            <caption>
              <p>Comparison of the rendered target TPKO signaling pathways identified by the SPIA method from GSE22873_MvA (KO Myd88 vs. KO Ager). Explanations are presented in the main text. <bold>(A)</bold> The MAPK signaling pathway (mmu04010). <bold>(B)</bold> The NF-kappa B signaling pathway (mmu04064). <bold>(C)</bold> The PD-L1 expression and PD-1 checkpoint pathway in cancer (mmu05235).</p>
            </caption>
            <graphic xlink:href="fimmu-14-1103392-g011" position="float"/>
          </fig>
        </sec>
        <sec id="s5_1_9_3">
          <label>5.1.9.3</label>
          <title>Scenario 3</title>
          <p>The treatment GSE22873_MvA (KO <italic>Myd88 vs.</italic> KO <italic>Ager</italic>) for a contrast between the <italic>Myd88</italic>-null and <italic>Ager</italic>-null mutants was interesting and plausible to elaborate the subtractive effects of KO <italic>Myd88</italic> against KO <italic>Ager</italic>. We identified 22 out of 23 significant TPKO signaling pathways (pGFdr &lt; 0.001 or 0.005) from it (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Table S7</bold></xref>). Firstly, two basal TPKO signaling pathways were significantly altered (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Table S7</bold></xref>; <xref rid="SM1" ref-type="supplementary-material"><bold>Figure S5</bold></xref>). (i) The Toll-like receptor signaling pathway (mmu04620) (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Table S7</bold></xref>; <xref rid="SM1" ref-type="supplementary-material"><bold>Figure S5A</bold></xref>) was ranked 2nd (with 55.17% DEGs out of the 87 critical genes) and was significantly inhibited. Key regulators (TLR2, TLR7/8, MyD88, CTSK, TAB1, p105, p38 and NFκB) were significantly down-regulated, whereas key regulators (MD2, PI3K, IRAK1, IRF7 and AP1 (FOS, JUN)) were significantly up-regulated. Such regulators constituted the TLR2-MyD88-IRAK1-TAB1-NFκB axis, the TLR2-PI3K-AKT-NFκB axis, the TLR7/8-MyD88-IRAK1-IRF7 axis, and the TLR2-MyD88-FADD-CASP8 axis. Activation of these axes resulted in up-regulation of inflammatory cytokines (IL1β and IL6) and down-regulation of inflammatory cytokines (IL12 and RANTES (CCL5)), which provoked proinflammatory effects and chemotactic (neutrophils and immature dendritic cells) effects at the systems-level. (ii) The AGE-RAGE signaling pathway in diabetic complications (mmu04933) (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Table S7</bold></xref>; <xref rid="SM1" ref-type="supplementary-material"><bold>Figure S5B</bold></xref>) was ranked 7th (with 36.73% DEGs out of the 98 critical genes) and was significantly activated. Key regulators (PLC, p38 and NFκB) were significantly down-regulated, whereas key regulators (PKC, PI3K, STAT3, STAT1/3, p21RAS, AP1 (FOS, JUN) and EGR1) were significantly up-regulated. Most importantly, activation of (i) the AGE-RAGE-PI3K-AKT-NFκB axis, coupled with the embedded PI3K-AKT signaling pathway, up-regulated IL1 and IL6, which are responsible for inflammation, as well as up-regulated VEGF, which is responsible for angiogenesis; (ii) alternatively, activation of the AGE-RAGE-PLC-PI3K-p38-AP1 axis or the AGE-RAGE-PI3K-ROS-p21RAS-p38-AP1 axis, coupled with the embedded MAPK signaling pathway and the calcium signaling pathway, up-regulated the expression of IL1, IL6 and VEGF; (iii) activation of the AGE-RAGE-JAK2-STAT3-axis, coupled with the embedded JAK-STAT signaling pathway, down-regulated the expression of PIM1, which is responsible for vascular remodeling; and (iv) activation of the AGE-RAGE-PKCβII-JNK-EGR1-axis increased the expression of EGR1-dependent genes leading to vascular dysfunction.</p>
          <p>Secondly, multiple composite TPKO signaling pathways were also targeted, as described below (<xref rid="f11" ref-type="fig"><bold>Figure 11</bold></xref>; <xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Table S7</bold></xref>). (i) The MAPK signaling pathway (mmu04010) (<xref rid="f11" ref-type="fig"><bold>Figure 11A</bold></xref>) was ranked 12th and was significantly activated (with 20.64% DEGs of the 281 critical genes) (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Table S7</bold></xref>). On the classical MAPK pathway, several key regulators (CACN, RTK, cPLA2 and NFκB) were significantly down-regulated, whereas other key regulators (GF, G12, GRB2, SOS, Ras, PKA, RSK2 and cFOS) were significantly up-regulated, which induced proliferation and differentiation. On the JNK/p38 MAPK pathway, several key regulators (MyD88, TAB1 and p38) were significantly down-regulated, whereas other key regulators (IL1, IRAK1/4, NFAT4 and AP1 (FOS, JUN)) were significantly up-regulated, which stimulated proliferation, differentiation and inflammation. (ii) The NFκB signaling pathway (mmu04064) (<xref rid="f11" ref-type="fig"><bold>Figure 11B</bold></xref>) was ranked 21st and was significantly inhibited (with 21.74% DEGs out of the 92 critical genes) (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Table S7</bold></xref>). Several key regulators (MyD88, NFκB (p50) and MIP2) were significantly down-regulated, whereas other key regulators (IL1β, MD2 and IRAK1/4) were significantly up-regulated, which resulted in increased IL1β leading to positive feedback and decreased MIP2 (CXCL1~CXCL3) leading to reduced inflammation. (iii) The PD-L1 expression and PD-1 checkpoint pathway in cancer (mmu05235) (<xref rid="f11" ref-type="fig"><bold>Figure 11C</bold></xref>) was ranked 15th and was significantly inhibited (with 33.33% DEGs of the 84 critical genes). Several key regulators (EGFR, TLR, MyD88, NFκB and p38) were significantly down-regulated, whereas other key regulators (PI3K, Ras, STAT, JUN, NFAT and AP1 (FOS, JUN)) were significantly up-regulated. Activation of the EGF-EGFR-Ras-Erk-AP1 axis coupled with the MAPK signaling pathway, the EGF-EGFR-PI3K-NFκB axis coupled with the PI3K-AKT signaling pathway, or the PAMPs-TLR-MyD88-NFAT/NFκB axis coupled with the Toll-like receptor signaling pathway stimulated the production of PD-L1 (CD274). The PD-L1/PD-1 complex led to further downstream effects, such as increased apoptosis as well as decreased IL-2 production, T-cell activation, effector T-cell development, and cell cycle progression. Auxiliary signaling pathways including the Toll-like receptor signaling pathway, the MAPK signaling pathway, the PI3K/AKT signaling pathway, the calcium signaling pathway, and the T-cell receptor signaling pathway were also embedded in the indicated target composite signaling pathways.</p>
        </sec>
      </sec>
    </sec>
    <sec id="s5_2">
      <label>5.2</label>
      <title>Case study 2: Evaluating the performance difference of pathway analysis methods</title>
      <sec id="s5_2_1">
        <label>5.2.1</label>
        <title>Assignment of a benchmark</title>
        <p>Based on the above comprehensive characterizations of individual data in this study and in our previous publication (<xref rid="B1" ref-type="bibr">1</xref>), we conclude that GSE22873_M, GSE22873_MA, GSE24327_A, GSE24327_B and GSE24327_C have strong signal to noise ratios when generated from the original bench-experiments (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>). These datasets are qualified to be included in a collection of qualified data that serves as a proper benchmark used to exemplify the different tasks in the present study (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Figure S2</bold></xref>).</p>
      </sec>
      <sec id="s5_2_2">
        <label>5.2.2</label>
        <title>All-in-all computations through batch-execution in a pipeline fashion</title>
        <p>The operational scripts depict batch-executions, exemplifying how target KO signaling pathways are automatically deciphered at the systems-level in a pipeline fashion, both across methods and across data (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Figure S3</bold></xref>). It takes approximately 25 minutes to complete the batch-computations across seven methods over one data on our high-performance workstation with the assigned configuration (see <xref rid="f1" ref-type="fig"><bold>Figure 1</bold></xref>; <xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Figure S1</bold></xref>). This is a time-limiting step.</p>
      </sec>
      <sec id="s5_2_3">
        <label>5.2.3</label>
        <title>Evaluating the performance difference of methods under the same conditions</title>
        <p>The ROC curve-based statistical analyses (e.g., violin plot and Wilcox test) are suitable for assessing the performance difference of the pathway analysis methods under comparison (<xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Figure S4</bold></xref>). The violin plot graph suggested that the topology-based methods (SPIA, ROntoTools_PE and ROntoTools_pDIS) generally performed better than the non-topology-based methods (GSEA, GSA, SAFF and PADOG); and that SPIA was overall better than ROntoTools_PE and ROntoTools_pDIS (<xref rid="f12" ref-type="fig"><bold>Figure 12</bold></xref>). These results coincide well with the findings of each individual data (see <xref rid="f6" ref-type="fig"><bold>Figures 6</bold></xref>, <xref rid="f7" ref-type="fig"><bold>7</bold></xref>, plus <xref rid="f2" ref-type="fig"><bold>Figure 2</bold></xref> therein Ref (<xref rid="B1" ref-type="bibr">1</xref>). However, the results of the Wilcox test (data not shown) on the global metrics (AUC, pAUC_SP and pAUC_SE) suggested that no significant difference was observed among methods when benchmarked on this collection of data.</p>
        <fig position="float" id="f12">
          <label>Figure 12</label>
          <caption>
            <p>Violin plot of key metrics indicates the performance difference of seven methods when benchmarked on a collection of five data. The topology-based methods (SPIA, ROntoTools_PE and ROntoTools_pDIS) generally perform better than the non-topology-based methods (GSEA, GSA, SAFF and PADOG). SPIA is overall better than ROntoTools_PE and ROntoTools_pDIS.</p>
          </caption>
          <graphic xlink:href="fimmu-14-1103392-g012" position="float"/>
        </fig>
      </sec>
      <sec id="s5_2_4">
        <label>5.2.4</label>
        <title>Key metrics suitable for a local comparison among methods</title>
        <p>Collected at the optimal <italic>p</italic>-Threshold, the key metrics (FDR, FPR, FNR, specificity, sensitivity, accuracy, precision and recall) reflect the local properties of the ROC curves and are suitable for a local comparison among methods (see <xref rid="T1" ref-type="table"><bold>Table 1</bold></xref>). With the chosen benchmark, the topology-based methods (SPIA, ROntoTools_PE and ROntoTools_pDIS) performed better than the non-topology-based methods (GSEA, GSA, SAFF and PADOG) in terms of <italic>p</italic>-Threshold and FDR; and GSEA displayed the poorest performance among the seven tested methods in terms of specificity, sensitivity, accuracy and precision (<xref rid="f12" ref-type="fig"><bold>Figure 12</bold></xref>).</p>
      </sec>
      <sec id="s5_2_5">
        <label>5.2.5</label>
        <title>Key metrics suitable for a global comparison among methods</title>
        <p>The key metrics including AUC, pAUC_SP and pAUC_SE reflect the overall properties of the ROC curves and are appropriate for a global comparison among methods (see <xref rid="T1" ref-type="table"><bold>Table 1</bold></xref>). The partial AUCs (pAUC_SP and pAUC_SE) of the 90–100% specificity and sensitivity may display drastic variations on a case-by-case basis, thus measuring possible bias toward a higher specificity (true negative rate) or higher sensitivity (true positive rate). With the chosen benchmark, ROntoTools_PE performed better than ROntoTools_pDIS in terms of AUC, pAUC_SP and pAUC_SE; and SPIA had a higher specificity (pAUC_SP) but a lower sensitivity (pAUC_SE) than GSEA (<xref rid="f12" ref-type="fig"><bold>Figure 12</bold></xref>).</p>
      </sec>
    </sec>
  </sec>
  <sec sec-type="discussion" id="s6">
    <label>6</label>
    <title>Discussion</title>
    <sec id="s6_1">
      <label>6.1</label>
      <title>Mechanisms underlying systems immunology triggered by sterile extensive hepatectomy</title>
      <p>Our results endorse the main findings of the original bench-experiments in view of the signaling effects on innate immune responses after extensive hepatectomy (<xref rid="B3" ref-type="bibr">3</xref>), as summarized below. (i) MyD88 and RAGE distinctly modulated inflammation, proliferation and apoptosis. (ii) Deletion of MyD88 gene (<italic>Myd88</italic> null) significantly decreased the survival rate. (iii) Deletion of RAGE gene (<italic>Ager</italic> null) significantly increased the survival rate. (iv) Deletion of RAGE gene modulated NFκB activation, up-regulated PIM1 expression and increased phospho-STAT3. These results suggest that blockade of RAGE might rescue liver remnants from the multiple signals that preclude adaptive proliferation triggered primarily by MyD88 signaling pathways. We hypothesize mechanisms underlying systems immunology triggered by the sterile 85% liver resection as early as 2 hours post-hepatectomy in the liver remnants of wild-type mice (<xref rid="f13" ref-type="fig"><bold>Figure 13</bold></xref>). We exemplify five TPKO signaling pathways, including the Toll-like receptor signaling pathway, the AGE-RAGE signaling pathway in diabetic complications, the MAPK signaling pathway, the NFκB signaling pathway, and the PD-L1 expression and PD-1 checkpoint pathway in cancer (<xref rid="f13" ref-type="fig"><bold>Figure 13</bold></xref>). Nonetheless, it does not necessarily mean that other target TPKO signaling pathways (see <xref rid="T2" ref-type="table"><bold>Table 2</bold></xref>; <xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Table S7</bold></xref>) should be excluded, nor should these target pathways be altered at the same time or in a single event; rather, these pathways are targeted because of massive signaling-crosstalk at the systems-level (see <xref rid="f9" ref-type="fig"><bold>Figures 9</bold></xref>–<xref rid="f11" ref-type="fig"><bold>11</bold></xref>; <xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Figure S5</bold></xref>), which are similar to those scenarios identified from the CASP-model sepsis previously discussed in detail (<xref rid="B1" ref-type="bibr">1</xref>). Hence, our results suggest diverse postinjury dysfunctions of the liver at the systems-level. This increases the difficulty of early diagnosis and prevention of liver failure after extensive hepatectomy because it is unlikely that systemic failures can be precisely attributed to a specific type of TPKO signaling pathway. Altogether, the hypothetical mechanisms we proposed from bioinformatics analysis and systems immunology provide novel informative cues that warrant bench-experimental validation at the systems-level in the future. We anticipate that such systems immunology in mice may serve as models for humans and ultimately guide formulating the research paradigms and composite strategies for the early diagnosis and prevention of diverse dysfunctions of livers post-hepatectomy in ICU patients who have undergone successful 85% hepatectomy for removing sick tissue and transplanting healthy tissue (<xref rid="B3" ref-type="bibr">3</xref>).</p>
      <fig position="float" id="f13">
        <label>Figure 13</label>
        <caption>
          <p>Hypothetical mechanisms underlying systems immunology triggered by extensive hepatectomy 2 hours post-resection in liver remnants. Key regulators are up (red)- and down (green)-regulated and marked on the indicated signaling axis coupled with target TPKO signaling pathways. These regulators coordinate MyD88 (<italic>Myd88</italic>) vs. RAGE (<italic>Ager</italic>) signaling transduction, thus orchestrating the regulation of innate inflammatory responses at the systems-level. The MyD88 signaling pathway responsible for proinflammatory responses is essential for survival consequent to 85% resection of the liver. MyD88 action stimulates the activation of NFκB and the subsequent up-regulation of key genes (including IL6) involved in liver regeneration responses. In contrast, RAGE opposes the actions of MyD88 signaling by suppressing NFκB, thereby reducing the activation of NFκB and the consequent production of cytokines (including IL1, IL1β, IL6, IL12 and CCL5), and by suppressing IL6-mediated phosphorylation of STAT3, which down-regulates PIM1 and reduces hyperplastic responses. The AP1 complex (FOS and JUN) acts as a hub in the present study. <bold>(A)</bold> Hepatocyte cytoplasm; <bold>(B)</bold> Hepatocyte nucleus; <bold>(C)</bold> Hepatocytes microenvironment (Tumor cells and T cells).</p>
        </caption>
        <graphic xlink:href="fimmu-14-1103392-g013" position="float"/>
      </fig>
      <p>Our results offer a better understanding of the mechanisms underlying the innate inflammatory responses triggered by sterile 85% liver resection (<xref rid="B3" ref-type="bibr">3</xref>) from the perspectives of bioinformatics analysis and systems immunology (<xref rid="f13" ref-type="fig"><bold>Figure 13</bold></xref>). The <italic>in vitro</italic> original bench-experiments suggested that some key regulators (RAGE, TRL4, NFκB and PIM1) were significantly increased at 6 hours when comparing hepatectomy wild-type mice to sham-surgery wild-type mice (<xref rid="B3" ref-type="bibr">3</xref>). Unfortunately, the microarray profiling data from sham-surgery wild-type mice were absent from the transcriptome of GSE22873 (<ext-link xlink:href="https://ncbi.nlm.nih.gov/geo/query/acc.cgi/GSE22873" ext-link-type="uri">https://ncbi.nlm.nih.gov/geo/query/acc.cgi/GSE22873</ext-link>) produced from tissues sampled at 2 hours post-hepatectomy (<xref rid="B3" ref-type="bibr">3</xref>), which hindered us from comparing hepatectomy against sham surgery in wild-type mice. However, in the present study, we can infer a virtual treatment, GSE22873_MvA (KO <italic>Myd88 vs.</italic> KO <italic>Ager</italic>), that reflects a virtual comparison between resected wild-type mice and untreated wild-type mice (see <xref rid="f11" ref-type="fig"><bold>Figure 11</bold></xref>; <xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Figure S5</bold></xref>). By which, we can elaborate the subtractive effects of KO <italic>Myd88</italic> over KO <italic>Ager</italic> by summarizing the up- and down-regulation of key regulators, as highlighted on the indicated signaling axis with target TPKO signaling pathways (see <xref rid="f11" ref-type="fig"><bold>Figure 11</bold></xref>; <xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Figure S5</bold></xref>). Thereby, we can further depict innate inflammatory responses at the systems-level to stimulus from the sterile 85% liver resection in wild-type mice, where the influences of attenuation or enhancement by the deletion of MyD88 and RAGE are inversely adapted (<xref rid="f13" ref-type="fig"><bold>Figure 13</bold></xref>). The critical regulators are differentially marked on target TPKO signaling pathways, such as TLR2/4, MyD88, RAGE, NFκB, PI3K, STAT3, NFAT, PIM1, IL1, IL1β, IL6, IL12 and RANTES (CCL5) (see <xref rid="f11" ref-type="fig"><bold>Figure 11</bold></xref>; <xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Figure S5</bold></xref>). These results are consistent with <italic>in vitro</italic> bench-experiment evidence (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B29" ref-type="bibr">29</xref>–<xref rid="B34" ref-type="bibr">34</xref>) and in line with recent reviews (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B35" ref-type="bibr">35</xref>–<xref rid="B37" ref-type="bibr">37</xref>). Intriguingly, the AP1 (FOS, JUN) complex emerges as a hub for the first time in this setting, and this complex plays a critical role in the signal transduction of DAMPs, PAMPs and AGEs that are triggered by extensive liver resection (<xref rid="f13" ref-type="fig"><bold>Figure 13</bold></xref>). DAMPs are released by damaged and dying cells (such as tumor cells) as endogenous host-derived molecules to promote sterile inflammation (<xref rid="B4" ref-type="bibr">4</xref>). DAMPs can also lead to the development of numerous inflammatory diseases, including autoimmune diseases, metabolic disorders, neurodegenerative diseases, and cancer (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>). The recognition of DAMPs is essential for tissue repair and regeneration (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>). The NFAT/AP1 transcriptional complex should be further explored, as a hub involved in regulating AP1-targeted genes at the systems-level (<xref rid="f13" ref-type="fig"><bold>Figure 13</bold></xref>). In addition to hepatocytes responding to stimulus from 85% hepatectomy (<xref rid="f13" ref-type="fig"><bold>Figures 13A, B</bold></xref>), the hepatocyte microenvironment is crucial to maintain proliferation, differentiation, apoptosis and inflammation (<xref rid="f13" ref-type="fig"><bold>Figures 13B, C</bold></xref>). Our findings are in line with recent advances in literature (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B39" ref-type="bibr">39</xref>). The NFAT/AP1 transcriptional complex was recently modulated by compounds that disrupt the NFAT : AP1:DNA complex, impairing transcription of cytokine genes (including IL2) important for the effector immune response (<xref rid="B38" ref-type="bibr">38</xref>). The transcription factor nuclear factor of activated T cells (NFAT) has a key role in both T-cell activation and tolerance and has emerged as an important target of immune modulation (<xref rid="B38" ref-type="bibr">38</xref>). NFAT directs the effector arm of the immune response in the presence of activator protein-1 (AP1), and T-cell anergy/exhaustion in the absence of AP1 (<xref rid="B38" ref-type="bibr">38</xref>). The PIM1/NFATc1 signaling pathway was recently suggested to be associated with impaired fibrosis resolution in aged mice after bleomycin injury (<xref rid="B39" ref-type="bibr">39</xref>).</p>
      <p>Nevertheless, we did not recapture the original bench-experiment observation that the RAGE-dependent suppression of Glo1 (i.e., a detoxification pathway for pre-AGEs) enhanced the levels of AGEs and fueled a mechanism suppressing IL6 action (<xref rid="B3" ref-type="bibr">3</xref>). The RAGE-mediated down-regulation of Glo1 increased the production of AGEs (i.e., RAGE ligand) in the remnant, and AGEs <italic>via</italic> RAGE antagonized IL6, which in turn reduced the phosphorylation of STAT3 and thus blocked the up-regulation of PIM1 in wild-type mice compared to RAGE-null mice (<xref rid="B3" ref-type="bibr">3</xref>). In fact, <italic>in vitro</italic> bench-experiments (Affymetrix gene arrays, quantitative real-time PCR/ChIP assays, immunoblotting assays, etc.) assessing target chemicals (AGE, IL6, phospho-STAT3 and PIM1) in hepatocyte remnants 2 hours post-injury affirmed the observation that AGE-RAGE suppressed the IL6-induced phosphorylation of STAT3 and the up-regulation of PIM1 expression (<xref rid="B3" ref-type="bibr">3</xref>). These results were consistent with data from <italic>ex vivo</italic> bench-experiments in which hepatocytes isolated from both WT and RAGE-null mice 2 hours after 85% liver resection were incubated under the indicated conditions (<xref rid="B3" ref-type="bibr">3</xref>). Remarkably, AGE molecules can mediate extracellular signals (e.g., inflammation, aging, oxidative stress, ischemia-reperfusion and high glucose) to the RAGE receptor, but RAGE (encoded by <italic>Ager</italic>) itself was not significantly up- or down-regulated in our current analysis when comparing deficient mice to wild-type mice (KO <italic>Ager vs</italic>. WT) (see <xref rid="f10" ref-type="fig"><bold>Figure 10</bold></xref>; <xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Figure S5).</bold></xref> Our findings tentatively suggest that RAGE may indirectly (<italic>via</italic> unclear epigenetics) regulate the KO RAGE (null <italic>Ager</italic>) phenotype and that more differentially expressed genes (DEGs) may be targeted and involved (see <xref rid="f9" ref-type="fig"><bold>Figures 9</bold></xref>–<xref rid="f11" ref-type="fig"><bold>11</bold></xref>; <xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Figure S5</bold></xref>; <xref rid="SM1" ref-type="supplementary-material"><bold>Tables S1</bold></xref>-<xref rid="SM1" ref-type="supplementary-material"><bold>S6</bold></xref>); further study is advised. We speculate that the expression of RAGE itself and the RAGE-dependent suppression of Glo1 impairing IL-6 activity were not dominant enough to be significantly detected as early as 2 hours post-surgery, born by the transcriptome, when comparing deficient mice to wild-type mice (see <xref rid="f10" ref-type="fig"><bold>Figure 10</bold></xref>; <xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Table S3</bold></xref>). The attractive role of RAGE-mediated epigenetics remains elusive.</p>
    </sec>
    <sec id="s6_2">
      <label>6.2</label>
      <title>Lessons from both non-infectious extensive hepatectomy and infectious CASP-model surgery</title>
      <p>Strikingly, our data indicate that sterile extensive hepatectomy (<xref rid="B3" ref-type="bibr">3</xref>) and septic CASP-model surgery (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>) share 21 KO MyD88-associated target TPKO signaling pathways, including the Toll-like receptor signaling pathway, the NFκB signaling pathway, the MAPK signaling pathway, and the PD-L1 expression and PD-1 checkpoint pathway in cancer, alongside the pathways of bacterial, viral and parasitic infections (see <xref rid="T2" ref-type="table"><bold>Table 2</bold></xref>; <xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Table S7</bold></xref>). These findings suggest that the two cases share common fundamental mechanisms underlying the innate inflammatory responses as early as 2 hours and 12 hours post-surgery, respectively (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>). We infer that the down-regulation of MyD88-signaling, as marked on target TPKO signaling pathways (see <xref rid="f9" ref-type="fig"><bold>Figure 9</bold></xref>), should significantly diminish proinflammatory responses by eliminating the downstream “cytokine storm”, similar to the scenario we previously discussed in infectious CASP-model sepsis (<xref rid="B1" ref-type="bibr">1</xref>). We speculate that such target TPKO signaling pathways could orchestrate the innate immune responses at the early stage of post-surgery before diverse dysfunctions of post-injured organs occur (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>). Our results offer valuable informative cues of systems immunology that warrant bench-experiment validation at the systems-level in the future. We anticipate that common fundamental mechanisms for both surgeries in mice may serve as models for humans and ultimately guide formulating research paradigms and prevention strategies for the early diagnosis and prevention of dysfunctions of multiple organs at the early stage of post-surgery, which in turn should reduce the high mortality rates of ICU patients who have undergone successful traumatic surgical treatments.</p>
      <p>Furthermore, our results favor recent proposals that TLRs, MyD88, RAGE and AGEs should have complex interactions to coordinate diverse mechanisms underlying innate immune responses at the systems-level (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B40" ref-type="bibr">40</xref>–<xref rid="B42" ref-type="bibr">42</xref>). Systems immunology triggered by MyD88- and TLRs-signaling in a wide range of immune-associated diseases, including mechanisms involved in diabetic complications (<xref rid="B43" ref-type="bibr">43</xref>), cardiovascular disease (<xref rid="B44" ref-type="bibr">44</xref>), metabolic disease (<xref rid="B44" ref-type="bibr">44</xref>) and other diseases associated with innate inflammatory signaling pathways (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B45" ref-type="bibr">45</xref>), deserves to be elusive in the context of gene-KO experiments through both experimental and computational analysis. Therefore, systems characterization of the immune landscapes of innate immune responses may dominate such research topics. We expect that the PathwayKO platform offers powerful tools for exploring such important topics and beyond.</p>
    </sec>
    <sec id="s6_3">
      <label>6.3</label>
      <title>The fundamental advantages of the PathwayKO platform</title>
      <p>The PathwayKO platform has currently incorporated several eminent methods that have been widely used by the community (see <xref rid="f1" ref-type="fig"><bold>Figure 1</bold></xref>). It was not our intention to choose the most prestigious method(s) to integrate into the PathwayKO platform; rather, we intended to create an integrated platform, flexible enough to incorporate promising methods and to evaluate them under the same context. Multiple aspects were considered as follows. (i) The choice of method is data-dependent since each method may have individual bias toward specific data (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B7" ref-type="bibr">7</xref>). It is difficult to predict in advance which method should be chosen (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>). (ii) Readers should be free to make their own judgments on proper method(s) toward data with complete resulting outputs in hand (see <xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Figures S2</bold></xref>-<xref rid="SM1" ref-type="supplementary-material"><bold>S4</bold></xref>); customers should also choose their favorite method(s) for routine analysis. (iii) It is possible for readers to remove methods that are performing consistently worse from the integrated PathwayKO platform by simply opting out of them when initializing parameters for a batch-execution (see <xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Figures S1</bold></xref>, <xref rid="SM1" ref-type="supplementary-material"><bold>S2</bold></xref>). (iv) The PathwayKO platform remains open to be constantly updated by incorporating new promising methods. Accordingly, we have established three fundamental advantages for the integrated PathwayKO platform, as highlighted below.</p>
      <p>Firstly, a ground truth is chosen for the PathwayKO platform based on whether or not the knockout gene itself is included in the predicted pathway to evaluate method performance, modified from the literature (<xref rid="B5" ref-type="bibr">5</xref>). We defined the TPKO (true positive knockout) signaling pathway as the pathway that comprises of, and is significantly impacted by, the KO gene, and is correctly identified as a significantly positive pathway (e.g., at the pathway-level <italic>p</italic>-value &lt; 0.0001). We further defined a set of terms modified from the literature (<xref rid="B5" ref-type="bibr">5</xref>), including FPKO, TNKO and FNKO signaling pathways, as described in the Methods section. Thereby, we defined a set of derivative metrics modified from the literature (<xref rid="B19" ref-type="bibr">19</xref>), including FDR, FPR, FNR, specificity, sensitivity, accuracy, precision, recall, AUC, pAUC_SP and pAUC_SE (see <xref rid="T1" ref-type="table"><bold>Table 1</bold></xref>). Such that the universal rules in computer science for direct measurements on a prediction accuracy can be fitted to pathway enrichment analysis, which differs from indirect measurements used by the community (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B46" ref-type="bibr">46</xref>).</p>
      <p>Secondly, for such a true-false case of prediction, the response versus prediction with a probability allows us employing the external pROC package (<xref rid="B19" ref-type="bibr">19</xref>) to build ROC curves and compute the set of key metrics (see <xref rid="T1" ref-type="table"><bold>Table 1</bold></xref>). The performance difference of pathway enrichment analysis methods can be evaluated in terms of the ROC curve-based statistics analysis for the first time in this setting (see <xref rid="f6" ref-type="fig"><bold>Figures 6</bold></xref>–<xref rid="f8" ref-type="fig"><bold>8</bold></xref>, <xref rid="f12" ref-type="fig"><bold>12</bold></xref>). Moreover, each point on an ROC curve represents a true KO (both TPKO and FNKO) signaling pathway in our cases; and an ROC curve represents the tradeoff between specificity and sensitivity for every possible <italic>p</italic>-value (<xref rid="B19" ref-type="bibr">19</xref>). The Youden’s best <italic>p</italic>-value threshold (denoted as <italic>p</italic>-Threshold) is a <italic>p</italic>-value that defines an optimal point (specificity, sensitivity) on an ROC curve (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B26" ref-type="bibr">26</xref>), where the sum of specificity and sensitivity is maximal (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B25" ref-type="bibr">25</xref>). Hence, collected at the optimal <italic>p</italic>-Threshold, some key metrics (FDR, FPR, FNR, specificity, sensitivity, accuracy, precision and recall) with local properties can be used to conduct a local comparison, while others (AUC, pAUC_SP and pAUC_SE) with global properties can be employed to perform a global comparison (see <xref rid="T1" ref-type="table"><bold>Table 1</bold></xref>). And such metrics are appropriate for evaluating the performance difference of methods (see <xref rid="f12" ref-type="fig"><bold>Figure 12</bold></xref>) and for assessing the quality of data (see <xref rid="f6" ref-type="fig"><bold>Figures 6</bold></xref>–<xref rid="f8" ref-type="fig"><bold>8</bold></xref>), both in terms of the ROC curve-based statistics analysis.</p>
      <p>Finally, the HES (high-edge-scores) approach and the change-point analysis method (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B26" ref-type="bibr">26</xref>) are employed to statistically select DEGs (see <xref rid="f2" ref-type="fig"><bold>Figures 2</bold></xref>, <xref rid="f4" ref-type="fig"><bold>4</bold></xref>, <xref rid="f5" ref-type="fig"><bold>5</bold></xref>) in a pipeline fashion. This approach exerts two advantages: (i) a fair comparison can be made among the methods integrated in the PathwayKO platform in a pipeline fashion, rather than conducted one by one in a manually-interfering manner. This also saves hundreds of hours from non-stop computations under the same conditions when a large-scale collection of (benchmark) data should be analyzed through a large-scale batch-computation (see <xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Figures S2</bold></xref>, <xref rid="SM1" ref-type="supplementary-material"><bold>S3</bold></xref>); and (ii) the resulting output files are automatically created and named after each data (see <xref rid="SM1" ref-type="supplementary-material"><bold>Supplemental Figures S3</bold></xref>, <xref rid="SM1" ref-type="supplementary-material"><bold>S4</bold></xref>). Thereby, a fair comparison can be pursued under the same conditions, and thus a fair choice of method (or data) can be made in the same context. These features allow readers to obtain complete and broad insights into customer data in a timely manner at the systems-level (<xref rid="B1" ref-type="bibr">1</xref>).</p>
    </sec>
    <sec id="s6_4">
      <label>6.4</label>
      <title>The prospects of the PathwayKO platform</title>
      <p>We note some limitations in the current status of the PathwayKO platform. Firstly, the complete resulting output files may be further integrated for more displaying ways, e.g., integrating the results into one output after applying a voting or merging mechanism (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>). Secondly, the PathwayKO platform deserves to explore other kinds of signaling pathways (<xref rid="B47" ref-type="bibr">47</xref>) (e.g., beyond the KO gene-associated signaling pathways defined by the choice of ground truth). For example, it might be possible that (i) a gene set containing a KO gene does not represent an actual regulated pathway (in the respective tissue and under respective condition, e.g., owing to epigenetic effects or missing co-factors); and (ii) the gene set of a truly affected pathway might not contain the KO gene. Thirdly, the PathwayKO platform does not fit to other kinds of data sources beyond GEO and KEGG pathways (<xref rid="B47" ref-type="bibr">47</xref>). Fourthly, a large-scale benchmark (constituted by KO transcriptomes) deserves to be created because a larger benchmark will yield a fairer comparison to evaluate the performance difference of methods under the same conditions (<xref rid="B5" ref-type="bibr">5</xref>). For which, qualified data must be selected, whose strong signals over noise must be validated through comprehensive characterizations, as revealed in the present study (see <xref rid="f6" ref-type="fig"><bold>Figure 6</bold></xref>). Finally, a large-scale benchmarking study toward gold-standard benchmarking remains to be explored, as another major challenge in the field (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B46" ref-type="bibr">46</xref>). All of these prospects deserve to be explored <italic>via</italic> updating the platform in the future.</p>
    </sec>
  </sec>
  <sec sec-type="conclusions" id="s7">
    <label>7</label>
    <title>Conclusion</title>
    <p>This article exemplified case studies associated with systems immunology to elaborate the methodology, principle and application features of the PathwayKO platform. The PathwayKO platform can comprehensively analyze gene-knockout (KO) transcriptomes to uncover mechanisms underlying systems immunology triggered by non-infectious extensive hepatectomy born by GSE22873 in the present study and by infectious CASP-model surgery born by GSE24327 in our previous publication. The PathwayKO platform model-based assessments on the performance of pathway analysis methods can also effectively evaluate the performance difference of methods when benchmarked on a collection of KO transcriptomes. A proper method toward data can be inferred. Taken together, we recommend the PathwayKO platform be applicable to broad fields (e.g., immunology, microbiology, genetics, pharmacology, cancers biology, cell and developmental biology, etc.) as long as KO transcriptomes are available.</p>
    <p>The PathwayKO platform is suitable for systems characterization of immune molecular landscapes of innate inflammatory responses in health, disease and clinical intervention cases through analyzing high-throughput transcriptomes from gene-knockout (KO) experiments. Real-world case studies suggest that both cases (GSE22873 and GSE24327) in the study share the same core set of 21 KO MyD88-associated target signaling pathways, including the Toll-like receptor signaling pathway, the NFκB signaling pathway, the MAPK signaling pathway, and the PD-L1 expression and PD-1 checkpoint pathway in cancer, alongside the pathways of bacterial, viral and parasitic infections. These findings suggest common fundamental mechanisms between the two cases and offer valuable insights into a better understanding of mechanisms underlying the innate inflammatory responses triggered by the non-infectious extensive hepatectomy (2 hours after 85% liver resection surgery in GSE22873) and the infectious CASP-model sepsis (12 hours after CASP-model surgery in GSE24327). Our results thus provide novel informative cues from the perspectives of bioinformatics analysis and systems immunology, which warrant further experimental validation in mice and may serve as models for humans.</p>
  </sec>
  <sec sec-type="data-availability" id="s9">
    <title>Data availability statement</title>
    <p>The original contributions presented in the study are included in the article/<xref rid="SM1" ref-type="supplementary-material"><bold>Supplementary Material</bold></xref>. Further inquiries can be directed to the corresponding authors.</p>
  </sec>
  <sec sec-type="author-contributions" id="s10">
    <title>Author contributions</title>
    <p>HA and YA designed the project HA designed and implemented the PathwayKO platform, conducted computations and analyzed data. HA, FM and YA interpreted results, wrote manuscript and approved the final manuscript. All authors contributed to the article and approved the submitted version.</p>
  </sec>
</body>
<back>
  <ack>
    <title>Acknowledgments</title>
    <p>The authors sincerely acknowledge TH-2 supercomputing resources in National Supercomputing Center at Guangzhou, Sun Yat-sen University. We sincerely thank numerous colleagues at Sun Yat-sen University and Guangzhou Medical University for their kind consultations on clinical cases under study. The authors gratefully acknowledge contributions by reviewers to improvement of the manuscript.</p>
  </ack>
  <fn-group>
    <title>Abbreviations</title>
    <fn fn-type="abbr">
      <p>GEO, gene expression omnibus; KEGG, Kyoto encyclopedia of genes and genome; DEGs, differentially expressed genes; FC, fold-change; RMA, robust multi-array average; FDR, false discovery rate; FPR, false positive rate; FNR, false negative rate; TNR, true negative rate; TPR, true positive rate; ROC, receiver operating characteristic; AUC, area under the ROC curve; pAUC_SP, partial AUC focusing on the specificity; pAUC_SE, partial AUC focusing on the sensitivity; HES, high-edge-scores; WT, wild-type; KO, knockout; MyD88, myeloid differentiating factor 88 (encoded by <italic>Myd88</italic>); TLR, toll-like receptor; AGEs, advanced glycation endproducts; RAGE, the receptor for advanced glycation end-products (encoded by <italic>Ager</italic>); DAMPs, damage-associated molecular patterns. PAMPs, pathogen-associated molecular patterns; NFκB, activation of nuclear factor kappa B; NFATc1, nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1; EGR1, early growth response 1; PIM1, proviral integration site 1; AP1 (FOS, JUN), FOS, FBJ osteosarcoma oncogene; JUN, jun proto-oncogene.</p>
    </fn>
  </fn-group>
  <sec sec-type="COI-statement" id="s12">
    <title>Conflict of interest</title>
    <p>HA was employed at SINOMACH-IT.</p>
    <p>The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest.</p>
  </sec>
  <sec sec-type="disclaimer" id="s13">
    <title>Publisher’s note</title>
    <p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
  </sec>
  <sec sec-type="supplementary-material" id="s14">
    <title>Supplementary material</title>
    <p>The Supplementary Material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2023.1103392/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fimmu.2023.1103392/full#supplementary-material</ext-link>
</p>
    <supplementary-material id="SM1" position="float" content-type="local-data">
      <media xlink:href="DataSheet_1.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <ref-list>
    <title>References</title>
    <ref id="B1">
      <label>1</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ai</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Meng</surname><given-names>F</given-names></name><name><surname>Ai</surname><given-names>Y</given-names></name></person-group>. <article-title>CASP-model sepsis triggers systemic innate immune responses revealed by the systems-level signaling pathways</article-title>. <source>Front Immunol</source> (<year>2022</year>) <volume>13</volume>:<elocation-id>907646</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2022.907646</pub-id>
<pub-id pub-id-type="pmid">35774781</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rime</surname><given-names>D</given-names></name><name><surname>Rossmann-Bloeck</surname><given-names>T</given-names></name><name><surname>Jusek</surname><given-names>G</given-names></name><name><surname>da Costa</surname><given-names>OP</given-names></name><name><surname>Holzmann</surname><given-names>B</given-names></name></person-group>. <article-title>Improved host defense against septic peritonitis in mice lacking MyD88 and TRIF is linked to a normal interferon response</article-title>. <source>J Leukoc Biol</source> (<year>2011</year>) <volume>90</volume>:<page-range>613–20</page-range>. doi: <pub-id pub-id-type="doi">10.1189/jib.1110602</pub-id>
</mixed-citation>
    </ref>
    <ref id="B3">
      <label>3</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>QY</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Vedantham</surname><given-names>S</given-names></name><name><surname>Rosario</surname><given-names>R</given-names></name><name><surname>Ananthakrishnan</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Opposing roles of RAGE and MyD88 signaling in extensive liver resection</article-title>. <source>FASEB J</source> (<year>2012</year>) <volume>26</volume>:<page-range>882–93</page-range>. doi: <pub-id pub-id-type="doi">10.1096/fj.11-192997</pub-id>
</mixed-citation>
    </ref>
    <ref id="B4">
      <label>4</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>R</given-names></name></person-group>. <article-title>DAMP-sensing receptors in sterile inflammation and inflammatory diseases</article-title>. <source>Nat Rev Immunol</source> (<year>2020</year>) <volume>20</volume>:<fpage>95</fpage>–<lpage>112</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41577-019-0215-7</pub-id>
<pub-id pub-id-type="pmid">31558839</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>T</given-names></name><name><surname>Shafi</surname><given-names>A</given-names></name><name><surname>Nguyen</surname><given-names>T</given-names></name><name><surname>Draghici</surname><given-names>S</given-names></name></person-group>. <article-title>Identifying significantly impacted pathways: a comprehensive review and assessment</article-title>. <source>Genome Biol</source> (<year>2019</year>) <volume>20</volume>:<fpage>203</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13059-019-1790-4</pub-id>
<pub-id pub-id-type="pmid">31597578</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanehisa</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Kawashima</surname><given-names>M</given-names></name><name><surname>Furumichi</surname><given-names>M</given-names></name><name><surname>Tanabe</surname><given-names>M</given-names></name></person-group>. <article-title>KEGG as a reference resource for gene and protein annotation</article-title>. <source>Nucleic Acids Res</source> (<year>2016</year>) <volume>44</volume>:<page-range>D475–62</page-range>. doi: <pub-id pub-id-type="doi">10.1093/nar/gkv1070</pub-id>
</mixed-citation>
    </ref>
    <ref id="B7">
      <label>7</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>T</given-names></name><name><surname>Mitrea</surname><given-names>C</given-names></name><name><surname>Draghici</surname><given-names>S</given-names></name></person-group>. <article-title>Network-based approaches for pathway level analysis</article-title>. <source>Curr Protoc Bioinf</source> (<year>2018</year>) <volume>1</volume>:<fpage>28</fpage>. doi: <pub-id pub-id-type="doi">10.1002/cpbi.42</pub-id>
</mixed-citation>
    </ref>
    <ref id="B8">
      <label>8</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>T</given-names></name><name><surname>Mitrea</surname><given-names>C</given-names></name><name><surname>Tagett</surname><given-names>R</given-names></name><name><surname>Draghici</surname><given-names>S</given-names></name></person-group>. <article-title>DANUBE: Data-driven meta-analysis using unbiased empirical distributions - applied to biological pathway analysis</article-title>. <source>Proc IEEE</source> (<year>2017</year>) <volume>105</volume>:<fpage>496</fpage>–<lpage>515</lpage>. doi: <pub-id pub-id-type="doi">10.1109/JPROC.2015.2507119</pub-id>
</mixed-citation>
    </ref>
    <ref id="B9">
      <label>9</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barry</surname><given-names>WT</given-names></name><name><surname>Nobel</surname><given-names>AB</given-names></name><name><surname>Wright</surname><given-names>FA</given-names></name></person-group>. <article-title>Significance analysis of functional categories in gene expression studies: a structured permutation approach</article-title>. <source>Bioinformatics</source> (<year>2005</year>) <volume>21</volume>:<page-range>1943–9</page-range>. doi: <pub-id pub-id-type="doi">10.1093/bioinformatics/bti260</pub-id>
</mixed-citation>
    </ref>
    <ref id="B10">
      <label>10</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Gillette</surname><given-names>MA</given-names></name><etal/></person-group>. <article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2005</year>) <volume>102</volume>:<page-range>15545–50</page-range>. doi: <pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id>
</mixed-citation>
    </ref>
    <ref id="B11">
      <label>11</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Efron</surname><given-names>B</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name></person-group>. <article-title>On testing the significance of sets of genes</article-title>. <source>Ann Appl Stat</source> (<year>2007</year>) <volume>1</volume>:<page-range>107–29</page-range>. doi: <pub-id pub-id-type="doi">10.1214/07-AOAS101</pub-id>
</mixed-citation>
    </ref>
    <ref id="B12">
      <label>12</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarca</surname><given-names>AL</given-names></name><name><surname>Draghici</surname><given-names>S</given-names></name><name><surname>Bhatti</surname><given-names>G</given-names></name><name><surname>Romero</surname><given-names>R</given-names></name></person-group>. <article-title>Down-weighting overlapping genes improves gene set analysis</article-title>. <source>BMC Bioinf</source> (<year>2012</year>) <volume>13</volume>:<elocation-id>136</elocation-id>. doi: <pub-id pub-id-type="doi">10.1186/1471-2105-13-136</pub-id>
</mixed-citation>
    </ref>
    <ref id="B13">
      <label>13</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breitling</surname><given-names>R</given-names></name><name><surname>Amtmann</surname><given-names>A</given-names></name><name><surname>Herzyk</surname><given-names>P</given-names></name></person-group>. <article-title>Iterative group analysis (iGA): a simple method to enhance sensitivity and facilitate interpretation of microarray experiments</article-title>. <source>BMC Bioinf</source> (<year>2004</year>) <volume>5</volume>:<elocation-id>34</elocation-id>. doi: <pub-id pub-id-type="doi">10.1186/1471-2105-5-34</pub-id>
</mixed-citation>
    </ref>
    <ref id="B14">
      <label>14</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goeman</surname><given-names>JJ</given-names></name><name><surname>Buehlmann</surname><given-names>P</given-names></name></person-group>. <article-title>Analyzing gene expression data in terms of gene sets: methodological issues</article-title>. <source>Bioinformatics</source> (<year>2007</year>) <volume>23</volume>:<page-range>980–7</page-range>. doi: <pub-id pub-id-type="doi">10.1093/bioinformatics/btm051</pub-id>
</mixed-citation>
    </ref>
    <ref id="B15">
      <label>15</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarca</surname><given-names>AL</given-names></name><name><surname>Draghici</surname><given-names>S</given-names></name><name><surname>Khatri</surname><given-names>P</given-names></name><name><surname>Hassan</surname><given-names>SS</given-names></name><name><surname>Mitta</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>A novel signaling pathway impact analysis</article-title>. <source>Bioinformatics</source> (<year>2009</year>) <volume>25</volume>:<fpage>75</fpage>–<lpage>82</lpage>. doi: <pub-id pub-id-type="doi">10.1093/bioinformatics/btn577</pub-id>
<pub-id pub-id-type="pmid">18990722</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Draghici</surname><given-names>S</given-names></name><name><surname>Khatri</surname><given-names>P</given-names></name><name><surname>Tarca</surname><given-names>AL</given-names></name><name><surname>Amin</surname><given-names>K</given-names></name><name><surname>Done</surname><given-names>A</given-names></name><name><surname>Voichita</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>A systems biology approach for pathway level analysis</article-title>. <source>Genome Res</source> (<year>2007</year>) <volume>17</volume>:<page-range>1537–45</page-range>. doi: <pub-id pub-id-type="doi">10.1101/gr.6202607</pub-id>
</mixed-citation>
    </ref>
    <ref id="B17">
      <label>17</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanoudi</surname><given-names>S</given-names></name><name><surname>Donato</surname><given-names>M</given-names></name><name><surname>Draghici</surname><given-names>S</given-names></name></person-group>. <article-title>Identifying biologically relevant putative mechanisms in a given phenotype comparison</article-title>. <source>PloS One</source> (<year>2017</year>) <volume>12</volume>:<elocation-id>e0176950</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0176950</pub-id>
<pub-id pub-id-type="pmid">28486531</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Killick</surname><given-names>R</given-names></name><name><surname>Eckley</surname><given-names>IA</given-names></name></person-group>. <article-title>Changepoint: An r package for changepoint analysis</article-title>. <source>J Stat Soft</source> (<year>2014</year>) <volume>58</volume>:<fpage>1</fpage>–<lpage>19</lpage>. doi: <pub-id pub-id-type="doi">10.18637/jss.v058.i03</pub-id>
</mixed-citation>
    </ref>
    <ref id="B19">
      <label>19</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robin</surname><given-names>X</given-names></name><name><surname>Turck</surname><given-names>N</given-names></name><name><surname>Hainard</surname><given-names>A</given-names></name><name><surname>Tiberti</surname><given-names>N</given-names></name><name><surname>Lisacek</surname><given-names>F</given-names></name><name><surname>Sanchez</surname><given-names>J-C</given-names></name><etal/></person-group>. <article-title>pROC: an open-source package for r and s+ to analyze and compare ROC curves</article-title>. <source>BMC Bioinf</source> (<year>2011</year>) <volume>12</volume>:<elocation-id>77</elocation-id>. doi: <pub-id pub-id-type="doi">10.1186/1471-2105-12-77</pub-id>
</mixed-citation>
    </ref>
    <ref id="B20">
      <label>20</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>W</given-names></name><name><surname>Brouwer</surname><given-names>C</given-names></name></person-group>. <article-title>Pathview: an R/Bioconductor package for pathway-based data integration and visualization</article-title>. <source>Bioinformatics</source> (<year>2013</year>) <volume>29</volume>:<page-range>1830–1</page-range>. doi: <pub-id pub-id-type="doi">10.1093/bioinformatics/btt285</pub-id>
</mixed-citation>
    </ref>
    <ref id="B21">
      <label>21</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carvalho</surname><given-names>BS</given-names></name><name><surname>Irizarry</surname><given-names>RA</given-names></name></person-group>. <article-title>A framework for oligonucleotide microarray preprocessing</article-title>. <source>Bioinformatics</source> (<year>2010</year>) <volume>16</volume>:<page-range>2363–7</page-range>. doi: <pub-id pub-id-type="doi">10.1093/bioinformatics/btq431</pub-id>
</mixed-citation>
    </ref>
    <ref id="B22">
      <label>22</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group>. <article-title>Linear models and empirical bayes methods for assessing differential expression in microarray experiments</article-title>. <source>Stat Appl Genet Mol Biol</source> (<year>2004</year>) <volume>3</volume>:<fpage>3</fpage>. doi: <pub-id pub-id-type="doi">10.2202/1544-6115.1027</pub-id>
</mixed-citation>
    </ref>
    <ref id="B23">
      <label>23</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritchie</surname><given-names>ME</given-names></name><name><surname>Phipson</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Law</surname><given-names>CW</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><etal/></person-group>. <article-title><italic>limma</italic> powers differential expression analyses for RNA-sequencing and microarray studies</article-title>. <source>Nucleic Acids Res</source> (<year>2015</year>) <volume>43</volume>:<fpage>e47</fpage>. doi: <pub-id pub-id-type="doi">10.1093/nar/gkv007</pub-id>
<pub-id pub-id-type="pmid">25605792</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>JD</given-names></name><name><surname>Wiemann</surname><given-names>S</given-names></name></person-group>. <article-title>KEGGgraph: a graph approach to KEGG pathway in r and bioconductor</article-title>. <source>Bioinformatics</source> (<year>2009</year>) <volume>25</volume>:<page-range>1470–1</page-range>. doi: <pub-id pub-id-type="doi">10.1093/bioinformatics/btp167</pub-id>
</mixed-citation>
    </ref>
    <ref id="B25">
      <label>25</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McClish</surname><given-names>DK</given-names></name></person-group>. <article-title>Analyzing a portion of the ROC curve</article-title>. <source>Med Decis Mak</source> (<year>1989</year>) <volume>9</volume>:<page-range>190–5</page-range>. doi: <pub-id pub-id-type="doi">10.1177/0272989X8900900307</pub-id>
</mixed-citation>
    </ref>
    <ref id="B26">
      <label>26</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Youden</surname><given-names>WJ</given-names></name></person-group>. <article-title>Index for rating diagnostic tests</article-title>. <source>Cancer</source> (<year>1950</year>) <volume>3</volume>:<page-range>32–5</page-range>. doi: <pub-id pub-id-type="doi">10.1002/1097-0142</pub-id>
</mixed-citation>
    </ref>
    <ref id="B27">
      <label>27</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>Y</given-names></name><name><surname>Hochberg</surname><given-names>Y</given-names></name></person-group>. <article-title>Controlling the false discovery rate: A practical and powerful approach to multiple testing</article-title>. <source>J R Statist Soc B</source> (<year>1995</year>) <volume>57</volume>:<fpage>289</fpage>–<lpage>300</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.2517-6161.1995.tb02031.x12</pub-id>
</mixed-citation>
    </ref>
    <ref id="B28">
      <label>28</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>Y</given-names></name><name><surname>Yekutieli</surname><given-names>D</given-names></name></person-group>. <article-title>The control of the false discovery rate in multiple testing under dependency</article-title>. <source>Ann Stat</source> (<year>2001</year>) <volume>29</volume>:<page-range>1165–88</page-range>. doi: <pub-id pub-id-type="doi">10.1214/aos/1013699998</pub-id>
</mixed-citation>
    </ref>
    <ref id="B29">
      <label>29</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cataldegirmen</surname><given-names>G</given-names></name><name><surname>Zeng</surname><given-names>S</given-names></name><name><surname>Ippagunta</surname><given-names>N</given-names></name><name><surname>Dun</surname><given-names>H</given-names></name><name><surname>Qu</surname><given-names>W</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappa b</article-title>. <source>J Exp Med</source> (<year>2005</year>) <volume>201</volume>:<fpage>473</fpage>–<lpage>484</lpage>. doi: <pub-id pub-id-type="doi">10.1084/jem.20040934</pub-id>
<pub-id pub-id-type="pmid">15699076</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nihira</surname><given-names>K</given-names></name><name><surname>Ando</surname><given-names>Y</given-names></name><name><surname>Yamaguchi</surname><given-names>T</given-names></name><name><surname>Kagami</surname><given-names>Y</given-names></name><name><surname>Miki</surname><given-names>Y</given-names></name><name><surname>Yoshida</surname><given-names>K</given-names></name></person-group>. <article-title>Pim-1 controls NF-kB signaling by stabilizing RelA/p65</article-title>. <source>Cell Death Differ</source> (<year>2010</year>) <volume>17</volume>:<page-range>689–98</page-range>. doi: <pub-id pub-id-type="doi">10.1038/cdd.2009.174</pub-id>
</mixed-citation>
    </ref>
    <ref id="B31">
      <label>31</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meloche</surname><given-names>J</given-names></name><name><surname>Paulin</surname><given-names>R</given-names></name><name><surname>Courboulin</surname><given-names>A</given-names></name><name><surname>Lambert</surname><given-names>C</given-names></name><name><surname>Barrier</surname><given-names>M</given-names></name><name><surname>Pierre Bonnet</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>RAGE-dependent activation of the oncoprotein Pim1 plays a critical role in systemic vascular remodeling processes</article-title>. <source>Arterioscler Thromb Vasc Biol</source> (<year>2011</year>) <volume>31</volume>:<page-range>2114–24</page-range>. doi: <pub-id pub-id-type="doi">10.1161/ATVBAHA.111.230573</pub-id>
</mixed-citation>
    </ref>
    <ref id="B32">
      <label>32</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name></person-group>. <article-title>Microarray approach reveals the relevance of interferon signaling pathways with rat liver restoration post 2/3 hepatectomy at the cellular level</article-title>. <source>J Interferon Cytokine Res</source> (<year>2010</year>) <volume>30</volume>:<page-range>525–39</page-range>. doi: <pub-id pub-id-type="doi">10.1089/jir.2009.0111</pub-id>
</mixed-citation>
    </ref>
    <ref id="B33">
      <label>33</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramasamy</surname><given-names>R</given-names></name><name><surname>Yan</surname><given-names>SF</given-names></name><name><surname>Schmidt</surname><given-names>AM</given-names></name></person-group>. <article-title>RAGE: therapeutic target and biomarker of the inflammatory response–the evidence mounts</article-title>. <source>J Leukoc Biol</source> (<year>2009</year>) <volume>86</volume>:<page-range>505–12</page-range>. doi: <pub-id pub-id-type="doi">10.1189/jlb.0409230</pub-id>
</mixed-citation>
    </ref>
    <ref id="B34">
      <label>34</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stepniak</surname><given-names>E</given-names></name><name><surname>Ricci</surname><given-names>R</given-names></name><name><surname>Eferl</surname><given-names>R</given-names></name><name><surname>Sumara</surname><given-names>G</given-names></name><name><surname>Sumara</surname><given-names>I</given-names></name><name><surname>Rath</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>C-Jun/AP-1 controls liver regeneration by repressing p53/p21 and p38 MAPK activity</article-title>. <source>Genes Dev</source> (<year>2006</year>) <volume>20</volume>:<page-range>2306–14</page-range>. doi: <pub-id pub-id-type="doi">10.1101/gad.390506</pub-id>
</mixed-citation>
    </ref>
    <ref id="B35">
      <label>35</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michalopoulos</surname><given-names>GK</given-names></name><name><surname>Bhushan</surname><given-names>B</given-names></name></person-group>. <article-title>Liver regeneration: biological and pathological mechanisms and implications</article-title>. <source>Nat Rev Gastroenterol Hepatol</source> (<year>2021</year>) <volume>8</volume>:<fpage>40</fpage>–<lpage>55</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41575-020-0342-4</pub-id>
</mixed-citation>
    </ref>
    <ref id="B36">
      <label>36</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiseleva</surname><given-names>YV</given-names></name><name><surname>Antonyan</surname><given-names>SZ</given-names></name><name><surname>Zharikova</surname><given-names>TS</given-names></name><name><surname>Tupikin</surname><given-names>KA</given-names></name><name><surname>Kalinin</surname><given-names>DV</given-names></name><name><surname>Zharikov</surname><given-names>YO</given-names></name></person-group>. <article-title>Molecular pathways of liver regeneration: A comprehensive review</article-title>. <source>World J Hepatol</source> (<year>2021</year>) <volume>13</volume>:<page-range>270–90</page-range>. doi: <pub-id pub-id-type="doi">10.4254/wjh.v13.i3.270</pub-id>
</mixed-citation>
    </ref>
    <ref id="B37">
      <label>37</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campana</surname><given-names>L</given-names></name><name><surname>Esser</surname><given-names>H</given-names></name><name><surname>Huch</surname><given-names>M</given-names></name><name><surname>Forbes</surname><given-names>S</given-names></name></person-group>. <article-title>Liver regeneration and inflammation: from fundamental science to clinical applications</article-title>. <source>Nat Rev Mol Cell Biol</source> (<year>2021</year>) <volume>22</volume>:<page-range>608–24</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41580-021-00373-7</pub-id>
</mixed-citation>
    </ref>
    <ref id="B38">
      <label>38</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mognol</surname><given-names>GP</given-names></name><name><surname>González-Avalos</surname><given-names>E</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Hogan</surname><given-names>PG</given-names></name></person-group>. <article-title>Targeting the NFAT:AP-1 transcriptional complex on DNA with a small-molecule inhibitor</article-title>. <source>PNAS</source> (<year>2019</year>) <volume>116</volume>:<page-range>9959–68</page-range>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1820604116</pub-id>
</mixed-citation>
    </ref>
    <ref id="B39">
      <label>39</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pham</surname><given-names>TX</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Guan</surname><given-names>J</given-names></name><name><surname>Caporarello</surname><given-names>N</given-names></name><name><surname>Meridew</surname><given-names>JA</given-names></name><name><surname>Jones</surname><given-names>DL</given-names></name><etal/></person-group>. <article-title>Transcriptional analysis of lung fibroblasts identifies PIM1 signaling as a driver of aging-associated persistent fibrosis</article-title>. <source>JCI Insight</source> (<year>2022</year>) <volume>7</volume>:<elocation-id>e153672</elocation-id>. doi: <pub-id pub-id-type="doi">10.1172/jci.insight.153672</pub-id>
<pub-id pub-id-type="pmid">35167499</pub-id></mixed-citation>
    </ref>
    <ref id="B40">
      <label>40</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prantner</surname><given-names>D</given-names></name><name><surname>Nallar</surname><given-names>S</given-names></name><name><surname>Vogel</surname><given-names>SN</given-names></name></person-group>. <article-title>The role of RAGE in host pathology and crosstalk between RAGE and TLR4 in innate immune signal transduction pathways</article-title>. <source>FASEB J</source> (<year>2020</year>) <volume>34</volume>:<page-range>15659–74</page-range>. doi: <pub-id pub-id-type="doi">10.1096/fj.202002136R</pub-id>
</mixed-citation>
    </ref>
    <ref id="B41">
      <label>41</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacLean</surname><given-names>M</given-names></name><name><surname>Derk</surname><given-names>J</given-names></name><name><surname>Ruiz</surname><given-names>HH</given-names></name><name><surname>Juranek</surname><given-names>JK</given-names></name><name><surname>Ramasamy</surname><given-names>R</given-names></name><name><surname>Schmidt</surname><given-names>MM</given-names></name></person-group>. <article-title>The receptor for advanced glycation end products (RAGE) and DIAPH1: Implications for vascular and neuroinflammatory dysfunction in disorders of the central nervous system</article-title>. <source>Neurochem Int</source> (<year>2019</year>) <volume>126</volume>:<page-range>154–64</page-range>. doi: <pub-id pub-id-type="doi">10.1080/14789450.2018.1536551</pub-id>
</mixed-citation>
    </ref>
    <ref id="B42">
      <label>42</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egaña-Gorroño</surname><given-names>L</given-names></name><name><surname>López-Díez</surname><given-names>R</given-names></name><name><surname>Yepuri</surname><given-names>G</given-names></name><name><surname>Ramirez</surname><given-names>LS</given-names></name><name><surname>Reverdatto</surname><given-names>S</given-names></name><name><surname>Gugger</surname><given-names>PF</given-names></name><etal/></person-group>. <article-title>Receptor for advanced glycation end products (RAGE) and mechanisms and therapeutic opportunities in diabetes and cardiovascular disease: Insights from human subjects and animal models</article-title>. <source>Front Cardiovasc Med</source> (<year>2020</year>) <volume>7</volume>:<elocation-id>37</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fcvm.2020.00037</pub-id>
<pub-id pub-id-type="pmid">32211423</pub-id></mixed-citation>
    </ref>
    <ref id="B43">
      <label>43</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senatus</surname><given-names>L</given-names></name><name><surname>López-Díez</surname><given-names>R</given-names></name><name><surname>Egaña-Gorroño</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Daffu</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>RAGE impairs murine diabetic atherosclerosis regression and implicates IRF7 in macrophage inflammation and cholesterol metabolism</article-title>. <source>JCI Insight</source> (<year>2020</year>) <volume>5</volume>:<elocation-id>e137289</elocation-id>. doi: <pub-id pub-id-type="doi">10.1172/jci.insight.137289</pub-id>
<pub-id pub-id-type="pmid">32641587</pub-id></mixed-citation>
    </ref>
    <ref id="B44">
      <label>44</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senatus</surname><given-names>L</given-names></name><name><surname>MacLean</surname><given-names>M</given-names></name><name><surname>Arivazhagan</surname><given-names>L</given-names></name><name><surname>Egaña-Gorroño</surname><given-names>L</given-names></name><name><surname>López-Díez</surname><given-names>R</given-names></name><name><surname>Manigrasso</surname><given-names>MB</given-names></name><etal/></person-group>. <article-title>Inflammation meets metabolism: Roles for the receptor for advanced glycation end products axis in cardiovascular disease</article-title>. <source>Immunometabolism</source> (<year>2021</year>) <volume>3</volume>:<elocation-id>e210024</elocation-id>. doi: <pub-id pub-id-type="doi">10.20900/immunometab20210024</pub-id>
<pub-id pub-id-type="pmid">34178389</pub-id></mixed-citation>
    </ref>
    <ref id="B45">
      <label>45</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Zou</surname><given-names>Z</given-names></name><name><surname>Meng</surname><given-names>F</given-names></name><name><surname>Raz</surname><given-names>E</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Tao</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Dust mite-derived der f 3 activates a pro-inflammatory program in airway epithelial cells <italic>via</italic> PAR-1 and PAR-2</article-title>. <source>Mol Immunol</source> (<year>2019</year>) <volume>109</volume>:<fpage>1</fpage>–<lpage>11</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.molimm.2019.02.018</pub-id>
<pub-id pub-id-type="pmid">30836204</pub-id></mixed-citation>
    </ref>
    <ref id="B46">
      <label>46</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maleki</surname><given-names>F</given-names></name><name><surname>Ovens</surname><given-names>K</given-names></name><name><surname>Hogan</surname><given-names>DJ</given-names></name><name><surname>Kusalik</surname><given-names>AJ</given-names></name></person-group>. <article-title>Gene set analysis: Challenges, opportunities, and future research</article-title>. <source>Front Genet</source> (<year>2020</year>) <volume>11</volume>:<elocation-id>654</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fgene.2020.00654</pub-id>
<pub-id pub-id-type="pmid">32695141</pub-id></mixed-citation>
    </ref>
    <ref id="B47">
      <label>47</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhee</surname><given-names>YS</given-names></name><name><surname>Wood</surname><given-names>V</given-names></name><name><surname>Dolinski</surname><given-names>K</given-names></name><name><surname>Draghici</surname><given-names>S</given-names></name></person-group>. <article-title>Use and misuse of the gene ontology annotations</article-title>. <source>Nat Rev Genet</source> (<year>2008</year>) <volume>9</volume>:<page-range>509–15</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nrg2363</pub-id>
</mixed-citation>
    </ref>
  </ref-list>
</back>
